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his document was developed by the American College of
ardiology Foundation (ACCF) Task Force on Clinical
xpert Consensus Documents (ECDs) and cosponsored by
he American College of Radiology (ACR), American
eart Association (AHA), American Society of Nuclear
ardiology (ASNC), North American Society for Cardio-
ascular Imaging (NASCI), Society of Atherosclerosis Im-
ging and Prevention (SAIP), Society for Cardiovascular
ngiography and Interventions (SCAI), and Society of
ardiovascular Computed Tomography (SCCT) to provide
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyperspective on the current state of computed tomographic
ngiography (CTA). ECDs are intended to inform practi-
ioners and other interested parties of the opinion of the
CCF and document cosponsors concerning evolving areas
f clinical practice and/or technologies that are widely
vailable or new to the practice community. Topics are
hosen for coverage because the evidence base, the experi-
nce with technology, and/or the clinical practice are not
onsidered sufficiently well developed to be evaluated by
he formal ACCF/AHA practice guidelines process. Often
he topic is the subject of ongoing investigation. Thus, the
eader should view the ECD as the best attempt of the
CCF and document cosponsors to inform and guide
linical practice in areas where rigorous evidence may not be
vailable or the evidence to date is not widely accepted.
hen feasible, ECDs include indications or contraindica-
ions. Some topics covered by ECDs will be addressed
ubsequently by the ACCF/AHA Practice Guidelines
ommittee.
The task force makes every effort to avoid any actual or
otential conflicts of interest that might arise as a result of
n outside relationship or personal interest of a member of
he writing panel. Specifically, all members of the writing
anel are asked to provide disclosure statements of all such
elationships that might be perceived as real or potential
onflicts of interest to inform the writing effort. These
tatements are reviewed by the parent task force, reported
rally to all members of the writing panel at the first
eeting, and updated as changes occur. The relationships
nd industry information for writing committee members
nd peer reviewers are published in Appendix 1 and Ap-
endix 2 of the document, respectively.
Robert A. Harrington, MD, FACC, FAHA
Chair, ACCF Task Force on
Clinical Expert Consensus Documents
. Introduction
.1. Writing Committee Organization
he writing committee consisted of acknowledged experts
n the field of CTA, as well as a liaison from the ACCF
ask Force on Clinical ECDs, the oversight group for this
ocument. In addition to 2 ACCF members, the writing
ommittee included 2 representatives from the ACR and
HA and 1 representative from ASNC, NASCI, SAIP,
CAI, and SCCT. Representation by an outside organiza-
ion does not necessarily imply endorsement.
.2. Document Development Process
.2.1. Relationships With Industry and Other Entities
t its first meeting, each member of the writing committee
eported all relationships with industry and other entities
elevant to this document topic. This information was
pdated, if applicable, at the beginning of all subsequent peetings and full committee conference calls. As noted in
he Preamble, relevant relationships with industry and other
ntities of writing committee members are published in
ppendix 1.
.2.2. Consensus Development
uring the first meeting, the writing committee discussed
he topics to be covered in the document and assigned lead
uthors for each section. Authors conducted literature
earches and drafted their sections of the document outline.
ver a series of meetings and conference calls, the writing
ommittee reviewed each section, discussed document con-
ent, and ultimately arrived at consensus on a document that
as sent for external peer review. Following peer review, the
riting committee chair engaged authors to address re-
iewer comments and finalize the document for document
pproval by participating organizations. Of note, telecon-
erences were scheduled between the writing committee
hair and members who were not present at the meetings to
nsure consensus on the document.
.2.3. External Peer Review
his document was reviewed by 15 official representatives
rom the ACCF (2 representatives), ACR (2 representa-
ives), AHA (2 representatives), ASNC (1 representative),
ASCI (2 representatives), SAIP (2 representatives), SCAI
2 representatives), and SCCT (2 representatives), as well as
0 content reviewers, resulting in 518 peer review com-
ents. See list of peer reviewers, affiliations for the review
rocess, and corresponding relationships with industry and
ther entities in Appendix 2. Peer review comments were
ntered into a table and reviewed in detail by the writing
ommittee chair. The chair engaged writing committee
embers to respond to the comments, and the document
as revised to incorporate reviewer comments where
eemed appropriate by the writing committee.
In addition, a member of the ACCF Task Force on
linical ECDs served as lead reviewer for this document.
his person conducted an independent review of the doc-
ment at the time of peer review. Once the writing
ommittee documented its response to reviewer comments
nd updated the manuscript, the lead reviewer assessed
hether all peer review issues were handled adequately or
hether there were gaps that required additional review.
he lead reviewer reported to the task force chair that all
omments were handled appropriately and recommended
hat the document go forward to the task force for final
eview and sign-off.
.2.4. Final Writing Committee and Task Force
ign-Off on the Document
he writing committee formally signed off on the final
ocument, as well as the relationships with industry that
ould be published with the document. The ACCF Task
orce on Clinical ECDs also reviewed and formally ap-
roved the document to be sent for organizational approval.
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he final version of the document, along with the peer
eview comments and responses to comments were circu-
ated to the ACCF Board of Trustees for review and
pproval. The document was approved in November 2009.
he document was then sent to the governing boards of the
CR, AHA, ASNC, NASCI, SAIP, SCAI, and SCCT for
ndorsement consideration, along with the peer review
omments/responses for their respective official peer review-
rs. ACCF, ACR, AHA, NASCI, SAIP, SCAI, and
CCT formally endorsed this document. This document
ill be considered current until the ACCF Task Force on
linical ECDs revises or withdraws it from publication.
.3. Purpose of This Expert Consensus Document
his document presents an expert consensus overview of the
urrent and emerging clinical uses of coronary CTA in
atients with suspected or known coronary artery disease
CAD). Since the evidence base for this technology is not
elt to be sufficiently mature to support a clinical practice
uideline at present, this ECD offers an alternative vehicle
n which the state of the art of coronary CTA can be
escribed without the requirement to provide explicit rec-
mmendations accompanied by formal ratings of the quality
f available evidence.
The intention of this document is to summarize the
trengths and weaknesses of current clinical uses of coronary
TA as reflected in the published peer-reviewed literature
nd as interpreted by the writing committee. The document
s not intended primarily as either a comprehensive litera-
ure review or as an instruction guide for those interested in
erforming or interpreting coronary computed tomography
CT) angiograms. The document also does not offer specific
tatements rating the appropriateness of various potential
linical uses of coronary CTA, as this has been dealt with in
he ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/
IR 2006 Appropriateness Criteria for Cardiac Computed
omography and Cardiac Magnetic Resonance Imaging
1). Finally, this document does not address the evaluation
f coronary calcium using CT, except as it pertains to CTA
tudies in patients with suspected or known CAD, since this
opic has also been covered in the ACCF/AHA 2007
linical Expert Consensus Document on Coronary Artery
alcium Scoring by Computed Tomography in Global
ardiovascular Risk Assessment and in Evaluation of Pa-
ients With Chest Pain (1a).
. Executive Summary
dvances in CT imaging technology, including the intro-
uction of multidetector row systems with electrocardio-
raphic gating, have made imaging of the heart and the
oronary arteries feasible. The potential to obtain informa-
ion noninvasively comparable to that provided by invasive
oronary angiography has been the major driving force behind the rapid growth and dissemination of cardiac CT
maging. In the future, the ability of CTA to provide
nformation not currently available from invasive angiogra-
hy may provide the basis for a major shift in how patients
ith atherosclerotic cardiovascular disease are classified and
anaged. Currently, cardiac CTA can provide information
bout coronary anatomy and left ventricular (LV) function
hat can be used in the evaluation of patients with suspected
r known CAD.
The technology for performing coronary CT angiograms
s evolving at a rate that often outpaces research evaluating
ts incremental benefits. Multidetector CT technology prior
o 64-channel or “slice” systems should now be considered
nadequate for cardiac imaging (except for studies limited to
ssessing coronary calcium). The incremental value of re-
ently introduced CT hardware with 128-, 256-, and
20-channel systems over 64-channel systems has not yet
een determined. As with any diagnostic technology, cor-
nary CTA has technical limitations with which users
hould be familiar, and proper patient selection and prepa-
ation are important to maximize the diagnostic accuracy of
he test. Most cardiac CTA examinations result in a large
-dimensional (4D) dataset of the heart obtained over the
ntire cardiac cycle. Physicians who interpret these exami-
ations must be able to analyze the image data interactively
n a dedicated workstation and combine knowledge of the
atient with expertise in coronary anatomy, coronary patho-
hysiology, and CT image analysis techniques and limita-
ions. In addition, integration of coronary CTA data into
linical practice requires that the results be evaluated in
erms of what was known diagnostically and prognostically
efore the test was performed and, thus, what incremental
nformation the test provides. The ability of a test such as
oronary CTA to provide incremental diagnostic informa-
ion that alters management (as contrasted with increasing
iagnostic certainty alone) is heavily dependent both on the
retest probability and on the alternative diagnostic strate-
ies considered.
The published literature on the diagnostic accuracy of
4-channel coronary CTA compared with invasive coronary
ngiography as of June 2009 consists of 3 multicenter cohort
tudies along with over 45 single-center studies, many of the
atter involving fewer than 100 patients. This literature
eflects careful selection of study subjects and test interpre-
ation by expert readers, typically with exclusion of patients
ho would be expected to have lower quality studies, such as
hose with irregular heart rates (e.g., atrial fibrillation),
besity, or inability to comply with instructions for breath
olding. In addition, because the cohorts for these studies
ere assembled from patients referred for invasive coronary
ngiography, they do not necessarily reflect, in terms of
bstructive CAD prevalence or clinical presentation, the
opulation to which coronary CTA is most likely to be
pplied in clinical practice. Accepting these caveats, some
onsistent conclusions emerge from this literature that may
e useful in clinical decision making. In these studies,
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyverall sensitivity and specificity on a per-patient basis are
oth high, and the number of indeterminate studies due to
nability to image important coronary segments in the select
ohorts represented is less than 5%. In most circumstances,
negative coronary CT angiogram rules out significant
bstructive coronary disease with a very high degree of
onfidence, based on the post-test probabilities obtained in
ohorts with a wide range of pretest probabilities. However,
ost-test probabilities following a positive coronary CT
ngiogram are more variable, due in part to the tendency to
verestimate disease severity, particularly in smaller and
ore distal coronary segments or in segments with artifacts
aused by calcification in the arterial walls. At present, data
n the prognostic value of coronary CTA using 64-channel
r greater systems remain quite limited. Furthermore, no
arge-scale studies have yet made a direct comparison of
ong-term outcomes following conventional diagnostic im-
ging strategies versus strategies involving coronary CTA.
As with invasive coronary angiography, the results of
oronary CTA are often not concordant with stress single-
hoton emission computed tomography (SPECT) myocar-
ial perfusion imaging (MPI). The differences in the pa-
ameters measured by MPI (“function” or “physiology”) and
TA (“anatomy”) must be considered when making patient
anagement decisions with these studies. Of note, a normal
PI does not exclude the presence of coronary atheroscle-
osis although it does signify a very low risk of future major
dverse events over the short to intermediate term. Con-
ersely, coronary CTA allows detection of some coronary
therosclerotic plaques that are not hemodynamically sig-
ificant. The optimal management of such disease has not
een established. Neither test can presently identify with
ny reasonable clinical probability nonobstructive coronary
laques that might rupture in the future and cause acute
yocardial infarction (MI). Invasive coronary angiography
as a similar limitation.
Studies comparing coronary CTA with fractional flow
eserve (FFR) measured as part of invasive coronary angio-
raphic studies complement the MPI comparisons de-
cribed in the preceding text by showing that coronary CTA
natomic data do not provide very accurate insights into the
robability that specific lesions will produce clinically sig-
ificant ischemia. Similar observations have been made
bout the relationship of FFR data and the anatomic
nformation provided by invasive coronary angiography.
In the context of the emergency department evaluation of
atients with acute chest discomfort, currently available data
uggest that coronary CTA may be useful in the evaluation
f patients presenting with an acute coronary syndrome
ACS) who do not have either acute electrocardiogram
ECG) changes or positive cardiac markers. However,
xisting data are limited, and large multicenter trials com-
aring CTA with conventional evaluation strategies are
eeded to help define the role of this technology in this
ategory of patients. dCoronary CTA imaging of patients with prior coronary
ypass surgery yields very accurate information about the
tate of the bypass grafts but less accurate information about
he native arteries distal to the bypasses and the ungrafted
rteries. Because chest pain after bypass surgery might be
ssociated with disease progression in either a graft or a
ative coronary artery, the difficulty of accurately assessing
he native vessels is an important limitation for the clinical
se of coronary CTA in the post-bypass patient.
Coronary stents pose some significant technical chal-
enges for coronary CTA, since the metal in the stents may
reate several types of artifacts in the images. Special
lgorithms are now routinely used that may reduce some of
hese artifacts during image reconstruction. The literature
uggests that in patients who have large diameter stents,
ood image quality, and whose clinical presentation suggests
ow-to-intermediate probability for restenosis, 64-channel
oronary CTA can be used to rule out severe in-stent
estenosis. There are no studies that directly compare a
oronary CTA strategy with an invasive coronary angiog-
aphy strategy in patients with coronary stents, and such
ata will be required to understand the efficiencies and
radeoffs of these 2 strategies in this population.
The literature on the assessment of LV function using
ardiac CTA in patients with suspected or known CAD is
uch smaller than that for diagnostic coronary imaging.
ne likely reason is that echocardiography already provides
readily available, noninvasive means of assessing ventric-
lar function and wall motion and does so without exposing
atients to ionizing radiation or iodinated contrast agents.
Available comparisons with cardiovascular magnetic res-
nance (CMR) suggest that CTA estimation of LV ejection
raction is accurate over a wide range of values. Accuracy
ay, however, be reduced at higher heart rates due to
ifficulties in capturing end-systolic and end-diastolic
hases accurately. Use of some newer strategies to reduce
he radiation dose of coronary CTA studies, such as
equential scanning, will eliminate the ability to assess LV
unction with the same study.
The writing committee considered several emerging ap-
lications where empirical data were deemed insufficient to
upport development of a consensus. Imaging of noncalci-
ed coronary plaques may in the future become a useful
pplication for coronary CTA, but it has no role in current
ractice since there are insufficient data to assess its clinical
tility. CTA assessment of total atherosclerotic burden and
otential plaque vulnerability similarly will require substan-
ial additional technical development and clinical investiga-
ion to define their potential value in patient management.
The writing committee identified 3 areas without con-
ensus: the interpretation of incidental noncardiac findings
n the CT examination, the use of coronary CTA in
symptomatic subjects, and the “triple rule-out” examina-
ion of patients with acute chest pain in the emergency
epartment.
t
t
p
M
t
c
n
a
m
M
r
r
2
a
t
i
d
a
c
i
e
s
e
e
e
c
3
T
c
e
T
q
p
m
a
d
t
t
s
g
r
m
r
h
E
S
a
t
m
a
b
s
p
c
s
t
4
B
N
a
l
C
p
r
t
p
l
e
i
s
j
p
r
t
t
I
p
c
d
b
S
4
I
s
s
m
a
c
e
a
i
e
a
n
i
a
a
t
t
s
2668 Mark et al. JACC Vol. 55, No. 23, 2010
Expert Consensus on CT Angiography June 8, 2010:2663–99Use of coronary CTA raises 2 important safety issues: 1)
he amount of radiation absorbed by the body tissues; and 2)
he exposure to iodinated contrast agents that have the
otential to produce allergic reactions and acute renal injury.
edian effective radiation dose (which is a calculated rather
han empirically measured quantity) for coronary CTA with
urrent technology was 12 mSv in a cross-sectional inter-
ational study of 50 sites (both academic and community)
ssessed in 2007. Individual sites in this study varied from a
edian of 5 to 30 mSv. In a 15-hospital imaging registry in
ichigan in 2007, prospective use of a set of best practice
adiation dose reduction recommendations resulted in a
eduction in the average scan effective radiation dose from
1 mSv to 10 mSv with no reduction in image quality.
Several preliminary economic studies using claims data
nd/or modeling have examined the use of coronary CTA in
he diagnostic evaluation of suspected coronary disease and
n the evaluation of acute chest pain in the emergency
epartment. Within the limits imposed by the data avail-
ble, these studies suggest that a diagnostic strategy using
oronary CTA may potentially reduce both the time spent
n the diagnostic process and the overall costs of clinical
valuation in selected populations, particularly in lower-risk
ubjects who otherwise would have been subjected to more
xpensive and possibly less accurate testing strategies. How-
ver, longer-term empirical studies will be required to
stablish the full economic impact of this technology in
ontemporary practice.
. Perspective and Scope of This Document
his document focuses on the perspective of clinicians
aring for patients with suspected or known CAD in
valuating the potential current uses for cardiac CTA.
herefore, the use of cardiac CTA for other primary clinical
uestions, such as the diagnosis of pulmonary embolism,
ulmonary parenchymal disease, pericardial disease, cardiac
asses, arrhythmogenic right ventricular dysplasia, thoracic
ortic disease, and congenital heart disease will not be
irectly addressed. Such disorders, of course, are relevant to
he subject matter of this report when they are identified by
he cardiac CT angiogram as a possible cause of the patient’s
ymptoms. This report does consider cardiac CT angio-
raphic estimation of LV ejection fraction and evaluation of
egional wall-motion abnormalities because these findings
ay help refine the assessment of the severity and clinical
elevance of CAD. Detection of coronary calcium by CT
as been addressed in the ACCF/AHA 2007 Clinical
xpert Consensus Document on Coronary Artery Calcium
coring by CT in Global Cardiovascular Risk Assessment
nd in Evaluation of Patients With Chest Pain (1a), and
herefore will not be considered here except where assess-
ent of coronary calcification is relevant to the performance
nd interpretation of coronary CTA. Information provided
y coronary CTA that is relevant to the patient with vuspected or known CAD is considered to the extent made
ossible by the available published evidence. The writing
ommittee felt that abstracts and oral presentations were not
ufficiently reliable sources to be used in the construction of
his document.
. Coronary CT Angiography:
rief Overview of the Technology
oninvasive coronary imaging requires a system capable of
cquiring motion-free, high spatial resolution images within
ess than 20 seconds, while patients are holding their breath.
urrent generation 64-channel multidetector row com-
uted tomography (MDCT) fulfills these requirements
easonably well (2). This section will briefly review selected
echnical and interpretive issues specifically relevant to the
erformance of MDCT coronary imaging. Readers of the
iterature should not be confused by the fact that several
quivalent terms are used to refer to this technology,
ncluding multidetector CT, multidetector row CT, multi-
lice CT, and multichannel CT.
Appropriate patient selection and preparation are ma-
or preimaging determinants of image quality. Key as-
ects of the imaging process include heart rate and
hythm control, the proper timing of the scan relative to
he introduction of the intravenous contrast bolus into
he circulation, and minimization of patient motion.
nteractive image reconstruction techniques are critical to
roper diagnostic interpretation but cannot remedy defi-
iencies in collection of raw radiographic data. The
eterminants of patient radiation dose and the trade-offs
etween radiation dose and image quality are discussed in
ection 11, Safety Considerations.
.1. Patient Selection and Preparation
mage quality of coronary CTA is improved by achieving a
low, regular heart rate, excluding very obese patients,
electing patients able to cooperate with instructions to be
otionless and to hold their breath during imaging, and by
ssessing the presence and distribution of coronary calcifi-
ation. All of these are evident from an initial patient
valuation except coronary calcification, which is typically
ssessed during the precontrast scans taken at the start of
maging. At present, there is no firm consensus on the
xtent of coronary calcification that precludes a technically
dequate coronary CT angiogram. Innovations in the scan-
ing process currently under investigation may reduce the
mportance of this issue in the future.
Patient preparation steps include achieving intravenous
ccess, typically in an antecubital vein suitable for contrast
dministration at a flow rate of 4 to 6 mL/s, and adminis-
ering preprocedure beta blockade when needed to achieve
he desired heart rate and rhythm. Administration of
ublingual nitroglycerin can be used to enhance coronary
asodilatation at the time of imaging. Rehearsal of the
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyreath hold with the patient improves compliance, serves to
ecrease patient anxiety, and may lessen motion artifact as a
esult. The rehearsal of breathing instructions can also be
sed as an opportunity to identify any unusual effects that
ight occur to heart rate and regularity from breath holding
n individual patients.
.2. Coronary CT Image Acquisition
T is an excellent method of creating high-resolution,
olumetric images of body structures that can be held
elatively stationary. In such situations, current generation
T systems can resolve very small, submillimeter, abnor-
alities. Movement of the target organ creates the need for
igh-temporal resolution to reduce motion-related blurring
rtifacts. Two kinds of motion, respiratory and cardiac,
ust be controlled during CT imaging of the coronary
rteries. Careful patient selection and preimaging coaching
an control respiratory motion via a voluntary breath hold.
reath-hold times on 64-channel systems for a cardiac
TA range from 10 to 15 seconds (may be shorter on
ystems with 128 channels or higher) and are well within the
apability of most patients, even those with respiratory
ompromise. Strategies to “control” cardiac motion rely on
combination of pharmacology and technology. The coro-
ary arteries move in a complex pattern through space
uring each cardiac cycle. Each coronary artery moves at a
ifferent velocity and in a different pattern from the others,
nd even the individual segments of each coronary do not
ove uniformly (3). Because coronary artery velocity and
cceleration during the cardiac cycle increase with higher
eart rates, preimaging heart rate control with beta blockers
s commonly used to slow coronary motion and is an
mportant part of patient preparation (4). In 1 multicenter
nternational study of 1965 patients undergoing coronary
TA, 12% of subjects were on daily beta blockers prior to
tudy and an additional 46% received beta blockers in
reparation for their scan (5). As the heart rate decreases,
he phase of relative cardiac quiescence in mid- to late-
iastole (at approximately 60% to 75% of the R to R
nterval) widens. With a sufficiently slow heart rate, typically
etween 50 to 65 beats per minute, ECG gating can be used
o select (retrospectively) the portion of the cardiac cycle for
mage reconstruction where the motion of each coronary
egment is at a minimum. Due to different patterns of
otion during the cardiac cycle, the optimal images for
efining details of the right coronary artery may occur in a
ifferent phase of the cardiac cycle from the optimal images
f the left coronary artery.
.2.1. Temporal Resolution of a CT Scan
he temporal resolution of a CT scan, or the ability to
esolve separate points in time, is determined in CT
cquisition by the time required to acquire the data for
econstruction of a single transverse section or “slice.” Thus,
he speed of gantry rotation (the gantry contains both the
-ray source and the detector array and is rotated around she patient during imaging) is one of the primary determi-
ants of the temporal resolution of the MDCT scan. The
inimum gantry rotation time on current generation scan-
ers (the time required to complete a 360° rotation) is
etween 280 and 400 ms, depending on the manufacturer
nd model. Tremendous centrifugal forces are created by
he need to spin the imaging components inside the gantry
round the patient and significant further increases in
otation times are limited by the ability of current mechan-
cal components to withstand such forces. Thus, alternative
ethods have been employed to further improve temporal
esolution. The routine use of half-scan reconstruction
esults in an effective temporal resolution of approximately
ne half the time required for the CT gantry to complete a
ingle 360° rotation or approximately 140 to 200 ms (6).
ther methods include the use of partial scan reconstruc-
ions from multiple adjacent cardiac cycles to improve
ffective temporal resolution. In 2007, a “dual-source” CT
canner was introduced that contained 2 X-ray sources and
sets of detectors offset 90° from each other in the CT
antry (7). This configuration is able to achieve an addi-
ional improvement in temporal resolution (to approxi-
ately 83 ms) by combining the data from the 2 detectors
sing just 90° of gantry rotation as opposed to the required
80° of gantry rotation needed with a single-source system
8). However, half-scan and partial-scan reconstructions
ay decrease spatial resolution due to misregistration arti-
acts. For reference, conventional invasive angiography us-
ng 30 frames per second has a temporal resolution of
pproximately 33 ms (9).
.2.2. Spatial Resolution of a CT Scan
patial resolution of a CT scan is defined in terms of the
n-plane or x-y axis resolution and the through-plane or
-axis resolution. The x-y spatial resolution of a CT scan is
he smallest distance between 2 high-contrast objects that
till allows recognizing the objects as separate. Modifiable
arameters that can affect in-plane resolution include the
econstruction algorithm that translates the projection data
nto planar images, the reconstructed field of view and the
mage matrix size (typically 512 512 pixels). The principal
imit on the z-axis, or “slice” resolution (along the patient’s
ong axis), lies in the detector array geometry. Within the
etector array are rows of array elements, which are typically
.4 to 0.6 mm in size along the z-axis. Thus, a “64-detector
ow CT” generally has 64 rows of detectors in its detector
rray. The width of the X-ray beam is collimated (i.e.,
hysically limited) in relation to the width of the detector
rray, which can vary among different CT systems from 20
o 160 mm along the z-axis.
During data acquisition, the CT system records the “raw”
can data and converts it to X-ray attenuation Hounsfield
nits (HUs). This file of raw projection data is used to
econstruct axial images, most commonly using a filtered
ack-projection algorithm (a standard algorithm for recon-
tructing CT images). Each image is reconstructed into a
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Expert Consensus on CT Angiography June 8, 2010:2663–9912  512 matrix for display. If the reconstructed image
as, for example, a field of view of 260 mm, the pixels in the
esulting image would have a nominal size of 0.5 mm  0.5
m (i.e., 260 mm/5120.5 mm). With detector elements
easuring 0.6 mm along the z-axis (see the preceding text),
his example would result in each volume data element, or
oxel, measuring 0.5 mm  0.5 mm  0.6 mm in the x, y,
nd z dimensions, respectively. These 3-dimensional (3D)
voxels” have the desirable property of being “near-
sotropic”: each voxel of the dataset has nearly the same size
n all 3 dimensions. What this means practically for physi-
ians is that the data can be displayed on a workstation in
ny plane or orientation without sacrificing spatial resolu-
ion. This capability is critical for cardiac and coronary
maging and allows visualization of the heart in the axial
lanes acquired as well as the short axis, vertical long axis
2-chamber), and horizontal long axis (4-chamber), all from
he same acquisition. For coronary imaging, the near iso-
ropic datasets provide views of each coronary artery seg-
ent along both its long axis and short axis (i.e., cross
ection).
For a coronary luminal diameter of about 3 mm, a cross
ection reconstructed from a CT scan with cubic voxel
imensions of 0.5 mm per edge will display the diameter of
he lumen using about 6 voxels. Because disease cannot be
esolved at the subvoxel level, the voxel size relative to the
bject being imaged defines the limits of quantitative
esolution. Thus, grading of coronary lesions with coronary
TA can be done at the ordinal level, but full quantification
emains problematic (10). For reference, invasive coronary
ngiography has a spatial resolution of about 0.16 mm (9).
hus, a 3-mm coronary artery lumen would be displayed
sing about 18 pixels, providing the opportunity for much
ore accurate quantification of disease affecting the coro-
ary artery lumen.
The number of longitudinal detector rows/data channels
hat can independently measure X-ray attenuation simulta-
eously determines the volumetric coverage of the CT
canner, or the amount of the cardiac volume (which in
dults is about 12 cm in the axial dimension) that is imaged
ith each CT gantry rotation. Using current generation
4-channel scanners, routine submillimeter imaging can be
erformed with scan durations of 10 to 20 seconds and
ongitudinal coverage of 20 to 40 mm of cardiac anatomy
er gantry rotation. However, a 64-channel CT system that
nvolves 32 detector rows and 2 focal spot positions (32 
64 data channels) does not have the same volumetric
overage as a system with 64 detector rows. To cover the
ntire heart in the most common mode of scanning,
ultiple 360° gantry rotations gated to the cardiac cycle are
sed as a motorized table moves the patient through the CT
canner. Thus, the X-ray beam traces a continuous helical
spiral) path around the section of the patient’s body being
maged.
Some institutions are now also using 128-channel scan-
ers, and both 256- and 320-channel scanners have been sntroduced (11). The latter configurations offer the potential
o image the entire heart during a single heartbeat (12,13).
hile this sounds like a theoretically attractive next step in
T technology, substantial technical challenges are imposed
y the creation of CT scanners that require the use of a cone
-ray beam as wide as 16 cm in the z-axis direction.
lthough volumetric coverage is increased with these new
canners, increasing the number of detector rows does not
y itself improve spatial or temporal resolution above that
rovided by 64-channel scanners. The benefits and limita-
ions of these newly introduced CT scanners will not be
nown until formal analyses of image quality, diagnostic
ccuracy, radiation dose, and clinical performance are eval-
ated in appropriate large multicenter studies.
Coronary CTA examinations are typically performed
sing nonionic intravenous contrast medium with high
odine concentration (greater than or equal to 300 to 350
g I/mL) to assure adequate opacification of the coronary
rtery lumen and sufficient contrast with the arterial wall.
his contrast injection is followed by injection of normal
aline to “push” contrast through the venous capacitance of
he upper extremity and the right heart structures (14). The
ontrast injection should result in a high-level plateau of
rterial opacification (greater than 300 to 350 HUs) during
T image acquisition. Several different methods, including
he use of a test bolus and automated bolus tracking, are
vailable to ensure that the period of maximum concentra-
ion of intravenously administered contrast material in the
oronary arteries is properly synchronized with the period of
can acquisition. If the contrast bolus arrives either too early
r too late, coronary image quality will be diminished, and
iagnostic information may be lost. Adult coronary CTA
equires the use of a high injection rate, typically 4 to 6
L/s, with the duration of injection and the volume of
ntravenous contrast agent prescribed based on the struc-
ures to be imaged and the specifics of the CT systems used
o acquire the exam.
.3. Image Reconstruction and Interpretation
mage reconstruction is the process of converting raw CT
ttenuation data into axial (i.e., transverse) sections. Al-
hough much of the process involves the use of proprietary
athematical algorithms developed by each manufacturer,
ome elements are under the control of the technician
orking with the study. Decisions that must be made
uring this initial processing of the data include use of
ptions for noise reduction and correction for any evident
lurring or motion artifact. In order to find the part of the
ardiac cycle that best captures motion-free images of the
ight and left coronary arteries, multiple phases of the
ardiac cycle may need to be reconstructed and examined.
ecisions about this are operator specific, with some choos-
ng to create up to 20 reconstructions at 5% increments of
he R to R interval (from 5% to 95%). Thus, a coronary CT
ngiogram may result in 350 to over 5000 transverse
ections available for physician examination, with most
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyoronary CT angiograms falling into a range of 1500 to
000 images.
The final phase of the CT angiogram study is the creation
f 2-dimensional (2D) reformatted images and 3D volume-
endered images from the transverse reconstructions. The
pproach to interpretation of a CT coronary angiogram
aries by operator, but some general principles can be
escribed. For most experts, the source transverse sections
upplemented with oblique reformations are the primary
ools for interactive interpretation of coronary CTA exam-
nations (15). In addition, interpretation of the transverse
ections provides a general understanding of the anatomic
elationships of the heart and coronary arteries with sur-
ounding structures such as the great vessels, nonvascular
ediastinal structures, lungs, and pleura. Comparisons of
bnormalities detected on reformatted or 3D-rendered im-
ges with the source transverse sections may help to mini-
ize errors in interpretation related to postprocessing arti-
acts.
Multiplanar reconstruction images can be oriented along
ny plane within the imaged volume, making it possible to
iew the long and short axis of the coronary artery segments
nd the cardiac chambers. Curved planar reformation im-
ges can be created manually or by using vessel centerline
racking algorithms to display the course of a coronary
rtery. Curved planar reformation images display the coro-
ary artery as if it were stretched along a hypothetical
traight line. Distortion is a concern with these reconstruc-
ions, particularly if vessel tortuosity creates difficulties for
he computer’s vessel-tracking calculations. Branch points
an similarly be problem areas. The maximum intensity
rojection is a visualization technique that combines data
rom a user defined “slab” (i.e., multiple adjacent “slices”) to
roduce a single summary image that displays the maximum
ntensity along each projection through the slab from the
erspective of the display (or viewer). This allows the course
f a contrast-filled coronary artery to be viewed as if one
ould see through the slab instead of only being able to see
he portion of the artery on the surface of the slab. To look
t the full length of a coronary artery, a “sliding slab”
echnique may be used that allows the operator to move the
lab along the entire course of the artery interactively (16).
Volume rendering provides a 3D reconstruction that can
e useful for displaying large amounts of data in a single
iew. The technique requires removing structures through
diting or by setting levels of opacity (windows) for display.
olume rendering can be valuable for understanding the
istribution of coronary arterial supply to the underlying
yocardium and the position and course of coronary bypass
rafts but is not considered reliable for detecting and
rading coronary stenoses. Neither volume-rendering im-
ges nor maximum-intensity projection images are sufficient
y themselves for assessing the distribution and severity of
oronary atherosclerosis.
As workstation capabilities improve, more complex re-
onstructions become possible, potentially reducing the rmount of physician time required for each study. At
resent, reconstruction is highly operator dependent. The
xtent to which variations among operators may influence
he quality of diagnostic information provided has not been
mpirically tested. In addition, there are no universally
ccepted conventions or standards for the display of cardiac
r coronary images, in contrast with echocardiography and
uclear cardiology. The SCCT has recently published a
onsensus document covering the interpretation and report-
ng of coronary CTA studies (17). The complexity of the
hysician–computer interaction poses substantial challenges
o those desiring to assess the performance of this technol-
gy, since it may be difficult to assess whether specific
spects of this interaction vary across centers and practices,
nd if so, whether the differences improve or impair diag-
ostic performance.
. Diagnostic Imaging of Coronary Arteries:
mportant Concepts
here are 2 basic diagnostic approaches to symptomatic
atients with chest pain, loosely referred to as “anatomic”
nd “functional.” Anatomic tests, such as coronary CTA
nd invasive coronary angiography, provide direct radio-
raphic visualization of the structural features of the coro-
ary artery lumen. Invasive coronary angiography creates a
D coronary “lumenogram.” By moving the fluoroscopy
nit, or by using a biplane system, multiple projections of
he lumen of each coronary artery can be obtained. To
stimate coronary artery stenosis severity from this tech-
ique, one must compare any evident narrowing of the
uminal outline with presumably normal adjacent segments
o allow estimation of a “percent diameter stenosis.” This
isual grading process, which is still the standard clinical
ethod of interpretation used in catheterization laboratories
round the world, has a high degree of intra- and interob-
erver variability (18–20). Computer-assisted interpreta-
ion, which could serve to reduce at least some of this
ariability, has not yet been accepted into routine clinical
ractice.
Invasive coronary angiography is considered the “refer-
nce standard” for diagnostic coronary testing, despite the
oregoing limitations, for several reasons. First, until the
dvent of 16-channel CT coronary angiography, it was the
nly method of directly visualizing the lumens of coronary
rteries that was suitable for routine clinical use. Second, the
ssessment of luminal stenosis severity on coronary angiog-
aphy, typically summarized in a very simple 1-, 2-, or
-vessel obstructive disease ranking, has been repeatedly
emonstrated to be one of the most important prognostic
actors in patients with coronary disease (21,22). Finally, the
esults of invasive coronary angiography have formed the
asis for revascularization treatment selection decisions for
lmost 40 years. Thus, invasive coronary angiography is the
eference standard in coronary assessment primarily because
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Expert Consensus on CT Angiography June 8, 2010:2663–99f the extensive evidence documenting its value in patient
anagement and secondarily because of its higher spatial
nd temporal resolution compared with alternative coronary
maging options.
The extensive evidence base relating invasive angiography
esults to prognosis and patient management cannot neces-
arily be extrapolated to the findings of coronary CTA.
owever, it is worth noting that invasive coronary angiog-
aphy itself has undergone major changes in imaging meth-
dology, evolving from an analog film image intensifier
ystem to digital image generation using flat-panel detec-
ors. No empirical studies have yet examined whether this
hange in technology, which has had a significant impact on
he fundamental imaging characteristics as well as radiation
xposure, has altered the relationships between test results
nd patient outcomes.
Coronary CTA provides information about the coro-
ary lumen that approximates the information available
rom invasive coronary angiography. In addition, it pro-
ides information about the presence of nonobstructive
laque in the vessel walls. Invasive coronary angiography
s subject to uncertainties about whether the reference
egment itself is diseased with plaque and whether the
uminal narrowing is concentric or eccentric (19). Coro-
ary CTA is able to image the plaque that is external to
he lumen and display its relationship with the lumen. As
ith invasive coronary angiography, visual grading of
oronary segment narrowing by ranges of stenosis is the
urrent standard of practice and has been shown to
rovide useful clinical information relative to invasive
oronary angiography (10,23). Quantitative coronary
TA has been used in some research applications but is
ot currently a routine part of clinical interpretation
24 –26). In a recent multicenter study, visual and quan-
itative assessments of stenosis severity by coronary CTA
ere quite similar (23).
Functional tests assess the ability of coronary arteries
including their collateral vessels) to provide a sufficient
lood supply to the myocardium both at rest and during
xercise or pharmacological stress. The detection of
yocardial ischemia using this approach relies on mea-
uring parameters such as LV blood flow/perfusion pat-
erns or LV function and wall-motion patterns that
eflect the impact of reduced blood supply and its
onsequences. Functional testing data therefore reflect
oth the severity and consequences of obstructive CAD
nd are prognostically incremental to anatomic imaging
n several important clinical settings (27,28). The appar-
nt dissociation between anatomic imaging results and
unctional test results can be attributed to several issues
Table 1). Thus, despite the detailed anatomic informa-
ion it provides, CTA may not eliminate the need for
ssessing the functional significance of lesions of inter-
ediate or indeterminate severity. r. Assessment of Left Ventricular Function:
mportant Concepts
V function, as reflected by the ejection fraction, is the
ingle most important prognostic parameter in patients with
stablished CAD. In addition, LV size and regional wall-
otion data can influence decisions about appropriate
herapies. Several methods provide quantitative evaluation
f LV function, including transthoracic echocardiography
TTE), gated SPECT, radionuclide angiography, invasive
eft ventriculography, and cardiovascular magnetic reso-
ance. LV assessment by CTA is based on use of retrospec-
ive gating with reconstruction of up to 20 phases of the
ardiac cycle including end-systole and end-diastole. Many
f the desired LV functional calculations can be automated
sing the workstation software, although some operator
nteraction with manual correction is often required. Clin-
cal use of these CT-derived data requires proper under-
tanding of features unique to coronary CTA compared to
ther more familiar methods of assessing LV structure and
unction measures. Values for LV volume, LV ejection
raction, and LV mass for cardiac CTA have recently been
eported from a series of 103 apparently healthy adults free
f hypertension and obesity (mean age 51 years) (34).
The temporal resolution of current-generation 64-
hannel multidetector scanners, reviewed briefly in Section
, Coronary CT Angiography: Brief Overview of the
echnology, is less than that of echocardiography and
nvasive LV angiography. Cardiovascular magnetic reso-
ance can generate images with higher average temporal
esolution secondary to acquiring data over multiple cardiac
ycles. Limited temporal resolution of CTA is primarily
elevant at higher heart rates and with the use of single-
ource MDCT scanners because fewer discrete time points
f the cardiac cycle can be properly reconstructed, and may
roduce inaccuracies in LV parameter measures due to
mproper identification of end-diastole and end-systole. At
eart rates between 55 to 65 beats per minute, however,
urrent 64-channel CTA provides sufficient cine frame rates
o provide LV function information with accuracy compa-
able 1. Reasons for Dissociation Between Anatomic Imaging
est Results and Functional Test Results
Diameter stenosis is a crude indicator of resistance to blood flow. Coronary
blood flow is proportional to the fourth power of the radius of the cross-
sectional vessel area.
Other anatomic features can affect pressure gradient across a stenosis,
including morphology and length of stenosis, entrance, and exit angles.
Tone of myocardial microvasculature is also important in modulating
antegrade and collateral components of coronary blood flow.
The gold standard used to define ischemia will affect the apparent
performance of diagnostic tests for ischemia (29).
The ischemia-producing potential of intermediate severity lesions
(e.g., 50% to 70% diameter stenosis) is particularly difficult to assess (30–33).able to other noninvasive and invasive modalities.
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.1. Key Clinical Questions
linicians caring for a patient with suspected or known
AD typically consider 3 types of questions. First, is
oronary disease present in this patient, and if present, what
s its current extent? This is a diagnostic question and
ffectively addresses the likelihood of certain findings if a
eference standard test was performed. As discussed in the
receding text, invasive coronary angiography is the current
eference standard diagnostic test for defining the presence
nd severity of obstructive CAD based on luminal stenosis.
owever, this status is based more on demonstrated value in
efining prognosis and choosing treatment than on docu-
ented ability to provide accurate and reproducible assess-
ent of the extent and severity of coronary atherosclerosis.
ther technologies that can image the diseased vessel wall,
uch as intravascular ultrasound (IVUS), CMR, and optical
oherence tomography, may actually be a more appropriate
eference standard for some aspects of CTA’s diagnostic
erformance given the ability of CTA to image the vessel
all in addition to the lumen.
Second, is this patient likely to suffer a major fatal or
onfatal cardiovascular event in the foreseeable future? This
s a prognostic question and addresses the ability of CTA to
elp stratify risk.
Third, will CTA help clinicians alter management in
ays that lead to reduced risk of major adverse clinical
vents? This is a therapeutic question and addresses the ability
f the information derived from the test to help clinicians
lter patient outcome.
.1.1. Assessing Diagnostic Accuracy
esearch studies evaluating novel diagnostic tests should
onsider using study designs that minimize biases and
aximize generalizability. These designs often include the
ollowing features: 1) selection of the study patients consec-
tively or at random from the target population at multiple
enters; 2) performance of both the new test of interest and
he reference standard test (e.g., coronary CTA and invasive
oronary angiography) in all patients in random order; 3)
nterpretation of both tests by multiple readers who are
ompletely blinded to any clinical information including the
esults of other tests and who reflect the spectrum of readers
ikely to interpret the test in clinical practice; 4) assessment
f intra- and interobserver variability for both studies. These
ethodological ideals have rarely been achieved in practice
or any noninvasive imaging test, due to logistics, funding,
nd other barriers. As a consequence, a number of impor-
ant biases may distort measured diagnostic performance.
or example, most studies of the diagnostic accuracy of
TA have focused on patients who were already referred for
nvasive coronary angiography (24,35). While this study
esign is appropriate if CTA will be used as a direct
eplacement for invasive angiography, it is not ideal if the (tudy population is substantially different from the one in
hich the test is most likely to be used clinically. Although
ecognition of such potential biases is an important part of
he due diligence involved in vetting any new test for clinical
ractice, it is also important to recognize that virtually all
he tests already accepted as a part of routine clinical
ractice, including stress nuclear and stress echo tests, had
imilar bias problems in their initial assessment and reported
iagnostic performance (36). A few of the more important
ias problems that occur regularly in the diagnostic testing
iterature are summarized in Table 2.
What clinicians most want to know from the use of tests
or diagnostic purposes are the post-test probabilities: “given
he observed test result, what is the new (revised) probability
y patient does/does not have disease?” These probabilities
re often referred to as “predictive values,” but this latter
erm has been a source of confusion to many in that it
mplies that these probabilities are fixed performance char-
cteristics of diagnostic tests. Post-test probability, on the
ther hand, clearly indicates an estimate that is a revision of
n earlier estimate (the pretest probability). To calculate
hese probabilities, one can employ Bayes’ formula for
imple cases or logistic regression models for more complex
ases. Most of the predictive value/post-test probabilities
eported in the coronary CTA literature are calculated from
he study sample using 2  2 tables of sensitivity/specificity
ersus obstructive CAD present/absent. Because these esti-
ates are valid for the study population from which they
ere derived, they may not be relevant to other patient
opulations. The critical factor to remember is that post-test
robabilities may vary importantly according to pretest
robability, and a given reported “predictive-value” figure
oes not apply across all possible pretest probabilities.
.1.2. Likelihood Ratios and Receiver-Operator
haracteristic Curves
ikelihood ratios and receiver-operator characteristic
able 2. Common Problems in Assessing Diagnostic
erformance of Diagnostic Tests
tudy Population Biases
Population chosen to evaluate performance of diagnostic test is not the one
in which the test will be used in practice.
erification Biases
Not all patients evaluated with new test also get reference standard test.
Use of reference standard test influenced by results of new test being
evaluated.
nterpretation Biases
Clinical interpretation used for research without a separate research-level
interpretation.
Spectrum of readers/interpreters does not reflect the eventual community of
practitioners who will use the test.
nalysis Biases
Exclusion of indeterminate or uninterpretable tests in evaluation of diagnostic
accuracy parameters.ROC) curves provide 2 useful and complementary ways of
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Expert Consensus on CT Angiography June 8, 2010:2663–99ummarizing diagnostic test accuracy. Neither is dependent
n disease prevalence per se, although both are affected by
hanges in the distribution of the severity of disease in the
opulation being tested. A likelihood ratio is the likelihood
f a given test result in a patient with disease relative to the
ame test result in a patient without disease (37). For a
ositive test, the likelihood ratio is calculated as (sensitivity/
1  specificity]), and higher values indicate that the test in
uestion is more accurate at identifying patients with
isease, particularly if the value is 10 or greater. For a
egative test, the likelihood ratio is calculated as ([1 
ensitivity]/specificity), and values less than 0.1 indicate a
est particularly accurate at ruling out disease.
ROC curves display in graphical form the relationship
etween the true positive rate of a test (its sensitivity) and its
alse positive rate (1  specificity) because the definition of
“positive” test is varied. Calculation of the area under the
OC curve provides a useful numeric summary measure
hat ranges from 1.0 (a perfect test) to 0.5 (a completely
oninformative test). Statistical comparison of the ROC
reas for 2 or more tests assessed in the same study
opulation may be used to identify the more accurate test
roviding that the curves are of similar shape.
.1.3. Assessing Prognostic Value
ecause not all diagnosed disease is clinically important,
ome have argued that a better sense of the value of a test
omes from its ability to stratify risk or prognosis. Adequate
rognostic studies require large samples and often long
eriods of follow-up. Hence, relatively young technologies
uch as coronary CTA often lack such data in the initial
ears of their clinical life. Problems arise in this literature
hen researchers attempt to circumvent some basic struc-
ural requirements of prognostic studies in order to generate
ata more quickly. A few of the more relevant caveats for
rognostic studies of diagnostic tests are summarized in
able 3.
.1.4. Assessing Therapeutic Value
etermination of the therapeutic value of a diagnostic test
s problematic because a test’s effects are inherently indirect.
nlike a drug or device that is intended to have a direct
mpact on a symptom or disease, diagnostic tests can only
mprove outcome by providing new information that
rompts changes of behavior among clinicians, patients, or
oth. No prospective randomized trials have yet examined
hether the current commonly used strategies of stress
esting improve patient outcomes. Nonetheless, therapeutic
alue has been demonstrated in clinical trials for some
iagnostic tests. Trials of invasive versus conservative man-
gement in ACS essentially tested diagnostic strategies
early versus deferred invasive coronary angiography) that
ere closely linked to decisions about revascularization,
hich in turn had the potential to affect outcome (38,39).
andomized trials have shown that screening mammogra-
hy (40) and abdominal aortic ultrasonography (41) save aives. Stratified analyses of treatment trials have shown that
roponin can be used to identify patients who will benefit
rom invasive management of ACS (42). However, the
roposition that diagnostic tests must be directly shown to
ffect patient outcomes before being considered fully vali-
ated for clinical practice is controversial because few tests
ver reach this level of validation, and adequate funding for
uch trials is extremely difficult to obtain.
Typically, the value of additional prognostic data (includ-
ng anatomic imaging findings) has been tested by calculat-
ng improvement in predictive information content, as
eflected by statistical model likelihood chi-square values or
values and/or showing adjusted hazard ratios. Other
pproaches include calculation of c-indexes (43,44) and
roportion of subjects with reclassified risk (45). Measures
uch as these that reflect only statistical improvements in
nformation, however, do not necessarily translate into
hanges in clinical decision making. Without demonstrating
his latter effect, there is limited possibility of altering
atient outcomes and thus the true incremental value of the
est in clinical practice may be overestimated (44).
. Current Coronary CT Angiography
pplications
.1. Diagnostic Accuracy of Coronary CT Angiography
n Stable Patients With Suspected CAD
number of carefully done systematic reviews have exam-
ned the diagnostic performance of coronary CTA since the
able 3. Common Problems in Assessing Prognostic Value of
iagnostic Tests
hoice of End Point
End point chosen is either not clinically relevant or not objectively verifiable.
All-cause mortality end point is chosen but other clinically relevant outcomes
are not also measured.
Classification of cause of death is often problematic, even with an
independent events committee.
“Harder” nonfatal end points, such as nonfatal MI, require proper use of
verification testing (e.g., ECG, serum markers) or they may be missed.
“Softer” nonfatal end points, such as revascularization and hospitalization,
often represent arbitrary decisions by clinicians rather than surrogates for
disease progression.
ompleteness of Follow-Up
Patients who are lost to follow-up often have worse prognoses, and their
omission from a prognostic study can introduce serious biases.
ntervening Treatments or Events
If a new test being studied affects subsequent use of prognosis-modifying
therapies (e.g., medications, revascularizations), the relationship between
test results and patient outcome may be obscured.
tatistical Power and Number of End Points
Number of useable follow-up events, not number of patients, determines the
statistical power of a prognostic analysis. (Useful rule of thumb is 5 to 10
outcome events are needed for each prognostic variable/covariate
considered in the analysis.)
CG indicates electrocardiogram; and MI, myocardial infarction.dvent of 64-channel CT in 2004. Each represents a
s
b
s
p
6
o
t
c
o
l
t
J
c
d
v
p
c
p
c
b
s
t
p
d
o
i
r
i
s
i
o
a
A
c
p
t
p
o
m
w
t
p
d
p
i
t
o
q
s
d
s
b
s
e
o
o
t
a
r
r
a
C
(
l
I
b
p
m
6
t
r
p
w
c
a
t
c
c
t
H
l
c
m
c
E
m
t
y
P
i
p
p
s
i
t
a
m
t
m
a
m
2
c
b
3
u
t
2675JACC Vol. 55, No. 23, 2010 Mark et al.
June 8, 2010:2663–99 Expert Consensus on CT Angiographyomewhat different point in the evolution of the evidence
ase supporting this technology (46–52). In general, these
tudies have concluded that diagnostic accuracy has im-
roved as the technology evolved from 4- to 16- to
4-channel machines, along with a decrease in the number
f non-assessable coronary segments. As noted earlier, while
he proof of concept for coronary CTA as a clinical tool was
learly shown by studies of 16-channel CT, present state-
f-the-art performance is not considered achievable with
ess than 64-channel scanners due to improvements in
emporal and spatial resolution.
Over 45 single-center studies have been published as of
une 2009 examining the diagnostic performance of 64-
hannel CT in the identification of obstructive coronary
isease in comparison with invasive coronary angiography in
arious populations (50). This literature largely reflects the
erformance of expert readers studying highly selected
onvenience samples of patients. This literature serves
rimarily to extend the proof of concept that coronary CTA
an, under various selected circumstances, correctly identify
oth patients with and patients without significant coronary
tenosis, as defined by invasive angiography. The strength of
hese data lies in the relative consistency of reported
erformance despite the variety of institutions studying
ifferent target patients and using somewhat different meth-
ds to perform and interpret the studies. Weaknesses
nclude the small sample sizes, with most of the studies
eporting on fewer than 100 patients, and the obvious biases
nherent in studying a convenience sample already pre-
elected for cardiac catheterization. A related issue is the
nclusion in many studies of patients in whom the diagnosis
f CAD was known or very probable, such as patients with
history of MI or patients with prior revascularization.
lthough many of these reports are deficient in relevant
linical details about the patients studied, a few not only
rovide important clinical descriptors but also use these data
o formally estimate pretest probability of CAD with
reviously validated predictive models (53,54). The majority
f studies used CT machines from the same vendor, and
any employed the same workstation for post-processing as
ell. The number of interpreters for each study, whether
hey worked independently or in consensus, the use of
rospective blinding to clinical and other test data, and the
etails of the coronary CTA review and interpretation
rocess (including which types of reformations were used to
dentify and grade coronary lesions) varied substantially in
his literature. Interpretation of the reference invasive cor-
nary angiogram also varied with some investigators using
uantitative coronary angiography and others using visual
tenosis assessment only. Some reports defined significant
isease as greater than or equal to 50% diameter stenosis,
ome as greater than or equal to 70%, and a few examined
oth. In addition, some studies excluded small-diameter
egments (e.g., less than 1.5 to 2.0 mm), while others
valuated all segments regardless of size. gStudies have generally been consistent in finding less than
r equal to 5% of patients had nonevaluable scans (in whole
r in part). Nevertheless, significant potential for publica-
ion bias exists. Studies demonstrating poorer performance
re much less likely to be submitted to journals or favorably
eceived by the peer review process. In the most recent
eview covering studies published through November 2007,
verage per-patient sensitivity for identifying obstructive
AD was 98%, with average per-patient specificity of 88%
50). Likelihood ratios for a positive test averaged 8.0, while
ikelihood ratios for a negative test averaged less than 0.1.
ndividual study specificities were reported over a much
roader range than sensitivities, and samples with higher
retest probabilities tended to report a lower specificity. The
ean prevalence of obstructive CAD in these studies was
1%. Post-test probabilities for a negative test (probability
hat the patient did not have disease given a negative test
esult, or “negative predictive values”) averaged 96% and
ost-test probabilities for a positive test averaged 93% but
ith a range from 64% to 100%.
Recently, 3 multicenter studies have been completed
omparing 64-channel coronary CTA with conventional
ngiography. These studies are notable both for the fact that
hey are the first multicenter studies of contemporary
oronary CTA diagnostic performance and that they used
areful research methodology in the collection and interpre-
ation of the CT and comparison catheterization data.
owever, as with the single institution papers, they are
imited by focusing on a population already selected for
oronary angiography. They also largely reflect the perfor-
ance of expert coronary CTA readers rather than
ommunity-based readers. The CORE 64 (Coronary Artery
valuation Using 64-Row Multidetector Computed To-
ography Angiography) study was conducted at 9 interna-
ional centers and enrolled 316 symptomatic patients age 40
ears or more with suspected or known coronary disease.
atients with calcium scores less than 600 were referred for
nvasive coronary angiography, 291 (92%) of which com-
leted coronary CTA prior to invasive coronary angiogra-
hy (23). All centers used the same vendor’s 64-channel CT
ystem. Standardized scanning protocols were used, includ-
ng nitroglycerin administration and use of radiation reduc-
ion algorithms (55). Independent blinded core laboratories
nalyzed the data, both visually and using quantitative
ethods. Lesions greater than or equal to 50% by quanti-
ative coronary angiography in any vessel greater than 1.5
m in diameter were considered obstructive. The median
ge of the study population was 59 years, and 74% were
en. Fifty-eight percent had angina at the time of study,
0% had a prior MI, and 10% had a previous percutaneous
oronary intervention. The prevalence of obstructive CAD
y quantitative coronary angiography was 56%. Over 99% of
782 coronary segments were suitable for quantitative eval-
ation by CT. On a per-patient–based analysis, the sensi-
ivity of quantitative coronary CTA for detection of a
reater than or equal to 50% diameter stenosis was 0.85,
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Expert Consensus on CT Angiography June 8, 2010:2663–99ith a specificity of 0.90. The likelihood ratio for a positive
est was 8.5, while that for a negative test was 0.17. The
ost-test probability of significant CAD after a positive test
as 0.91, while the post-test probability that disease was
ruly absent after a negative test was 0.83. Two patients had
ignificant reactions to the contrast medium given for the
tudies. CTA was similar to invasive coronary angiography
n its ability to identify, based on the presence of greater
han 50% obstructive stenosis, those patients who were
ubsequently referred for revascularization. In addition, the
ormulation of CT data into a modified Duke prognostic
AD index correlated moderately well with the same index
onstructed from invasive coronary angiographic data
r0.81).
The ACCURACY (Assessment by Coronary Computed
omographic Angiography of Individuals Undergoing In-
asive Coronary Angiography) study prospectively enrolled
45 patients with typical or atypical chest pain who were
eferred for invasive coronary angiography at 16 (predomi-
antly nonacademic) U.S. sites and agreed to have a
oronary CTA prior to their catheterization (56). All CT
tudies were performed with the same 64-channel CT
ystem. The CT studies were interpreted by a consensus of
t least 2 of 3 independent readers (2 academic, 1 nonaca-
emic) blinded to all clinical and diagnostic test data. No
oronary segments were excluded due to inability to evaluate
he extent of stenosis. A single reader who was blinded to all
linical and CT data interpreted the invasive coronary
ngiograms. Patients with known coronary disease were
xcluded. Of the 245 patients enrolled, 15 were excluded for
ailure to complete both study tests. The remaining 230
atients had a mean age of 57 years, and 59% were men.
ymptom status at the time of testing was not reported. By
uantitative coronary angiography, disease prevalence was
5% for any stenosis greater than or equal to 50% and 14%
or any stenosis greater than or equal to 70%. On a
er-patient basis (including 3 patients with discordant
eadings among the 3 readers), sensitivity of coronary CTA
as 94% to 95%, depending on the cutpoint chosen to
epresent a positive invasive coronary angiogram, and spec-
ficity was 82%. The likelihood ratio for a positive test was
.5 to 5.6 with the likelihood ratio for a negative test 0.06
o 0.07. Post-test probability for a negative test (negative
redictive value) was 99% for both disease definitions, but
ost-test probability after a positive test was 48% (with
isease prevalence of 14%) to 64% (with disease prevalence
f 25%).
Three university hospitals in the Netherlands prospec-
ively enrolled 433 symptomatic patients age 50 to 70 years
ho were referred for invasive coronary angiography (Oc-
ober 2004 to June 2006) (57). Of these, 62 patients
eclined a research coronary CTA, and 11 patients were
xcluded for various technical reasons, leaving a study
opulation of 360 subjects. No patients or coronary seg-
ents were excluded due to impaired image quality fromither motion or coronary calcium. Patients with previous sevascularization were excluded. All CT studies were per-
ormed within 2 weeks before or after invasive angiography.
ach center used a CT machine from a different vendor.
hree cardiologists unaware of the CT results graded each
nvasive angiogram. Significant coronary disease was re-
orded when the luminal diameter stenosis was greater than
r equal to 50%. Teams of 2 observers unaware of the
nvasive angiogram results graded the CT studies. Scans
rom each center were interpreted by a team from 1 of the
ther 2 centers. The mean age of the study population was
0 years, and 68% were men. Forty-two percent had typical
ngina, 21% had unstable angina, and 14% had a non–ST-
egment elevation MI. The prevalence of significant coro-
ary obstructive disease was 68%; sensitivity for CTA was
9% with a specificity of 64%. Two patients with single-
essel disease were missed. CT classified 41 patients with
ngiographically insignificant disease as having significant
oronary disease: 1-vessel disease in 20 patients, 2-vessel
isease in 11 patients, 3-vessel disease in 7 patients, and
ignificant left main disease in 3 patients. The likelihood
atio for a positive test was 2.7 and for a negative test was
.02.
In October 2009, the National Heart, Lung, and Blood
nstitute funded the PROMISE (PROspective Multicenter
maging Study for Evaluation of Chest Pain) trial, a
andomized trial of initial anatomic strategy using a 64-slice
r higher coronary CTA versus an initial functional stress
esting strategy in 10 000 low- to intermediate-risk patients
58). The primary outcome is a composite clinical event
ncluding death and MI, and follow-up will average 2.5
ears.
.1.1. Coronary Anatomic Subgroup Data
lthough patient-level accuracy data are most directly
elevant to patient management decisions, anatomic sub-
roup data can provide supplementary insights into areas of
oronary CTA strengths and weaknesses. In that regard, it
s particularly relevant to note that accuracy of coronary
TA for the highest-risk CAD subgroups seems very good.
n 13 studies, coronary CTA had a pooled sensitivity of
00% and specificity of 99% for detection of significant left
ain coronary disease (50). In the left anterior descending
LAD) artery, sensitivity was 93% and specificity was 95%.
n the left circumflex artery, sensitivity was 88% with a
pecificity of 95%. In the right coronary artery, sensitivity
as 90% with a specificity of 96%.
At the coronary segment level, of over 27 000 segments
eported, 7.8% were unevaluable (50). In 9 studies, sensi-
ivity in proximal segments was 93% with a specificity of
5%. Results were similar in midsegments, but in distal
egments, sensitivity was 80% with a specificity of 97%. The
egative likelihood ratio for distal segments was 0.2, indi-
ating that a finding of no distal disease by coronary CTA
s not as conclusive as the same finding in a more proximal
egment where the negative likelihood ratio was 0.07.
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tress Perfusion Imaging
he contrast between “anatomic” and “functional” diagnos-
ic testing has been reviewed earlier. Two different types of
tudies have been performed to compare the diagnostic
erformance of coronary CTA with stress MPI in identi-
ying obstructive CAD. The majority use the myocardial
erfusion study as the reference standard in lieu of invasive
ngiography (59–61). Several additional studies have re-
orted on patients who received coronary CTA, stress
yocardial perfusion testing, and invasive coronary angiog-
aphy, which permits more comparisons to be performed
ut are limited by virtue of being small, very select study
roups (33,62). This literature reinforces findings from the
iagnostic angiography literature showing that negative
oronary CTA results using contemporary equipment and
nalysis/interpretation methods provides a reliable exclusion
f clinically significant coronary disease. However, the
ccurrence of discordant patients with 1 test “positive” and
he other “negative” highlights the impact of different
eference standards in assessing the performance of coronary
TA. A few examples serve to illustrate these issues.
Lin et al. (60) studied 163 symptomatic patients without
nown CAD who underwent both coronary CTA and
xercise stress testing with SPECT imaging. The median
ime between exams was 111 days, indicating that this was
convenience sample that was subject to undefined selec-
ion biases. Thirty-nine patients (24%) had obstructive
laques identified on 64-channel CT, while 105 (64%) had
onobstructive plaque identified. Fifteen of 39 patients with
bstructive coronary disease had normal exercise perfusion
cans. Several scores reflecting various aspects of the extent
nd severity of CAD were predictive of the presence of
evere myocardial perfusion defects. However, there was no
ssociation between the distribution of coronary plaque by
T and the presence of exercise perfusion defects on nuclear
maging.
Ninety-two low-risk chest pain patients (with negative
CG and serum marker results) seen in the William
eaumont Hospital Emergency Department underwent
est/stress MPI and 64-detector coronary CTA as part of a
rospective study (63). Seven patients (8%) were excluded
ecause of uninterpretable coronary CTA scans leaving 85
atients in the analysis (mean age 49 years, 53% men).
hest pain was the presenting symptom in 94%. Both MPI
nd coronary CTA were negative in 66 patients (78%), and
oth were positive in 6 patients (7%). When judged against
he composite outcome of either definite ACS or significant
AD by invasive angiography in the subsequent 30 days,
he sensitivity of stress nuclear imaging was 71% and
oronary CTA was 86%, while the specificity was 90% and
2%, respectively.
A total of 114 patients (mean age 60 years, 85%
ntermediate pretest probability by Diamond and For-
ester algorithm) presenting to the outpatient clinic of deiden University with chest pain but without known
AD who had been referred for MPI underwent coro-
ary CTA as well within 1 month (33). The first 28
atients were studied with 16-channel MDCT, while the
emainder were studied with 64-channel scanners. Sixty-
ight percent of patients had normal myocardial perfu-
ion scans. Thirty-six percent of patients undergoing
oronary CTA had no CAD, while 29% had nonobstruc-
ive plaques. When the coronary CTA was normal
n41), 90% also had a normal MPI. In the 40 patients
ith obstructive CAD on coronary CTA, abnormal MPI
as observed in 50%, one third of which showed fixed
efects; and two thirds, reversible defects.
Ninety-six patients referred to the University of Zurich
or invasive angiography for known or suspected CAD
ere asked to also undergo both MPI and 64-channel
oronary CTA, in that order (62). Seven patients did not
ndergo coronary CTA because of atrial fibrillation, and
1 patients declined invasive angiography. The remaining
8 patients (mean age 65 years, 55% men) formed the
tudy population. Twenty-four percent had known CAD
nd prior revascularization. Coronary CTA was uninter-
retable in 5 patients, and the responsible segments were
ssumed to be diseased in an “intention-to-diagnose”
nalysis. By invasive angiography, 46 patients (63%) had
ignificant CAD (diameter reduction of greater than or
qual to 50% by quantitative analysis). MPI showed a
efect in 29 of the 46 patients, of which 19 were
eversible. In a patient-based analysis, coronary CTA had
sensitivity of 94% and specificity of 64% for identifica-
ion of patients with any perfusion defect. The positive
nd negative likelihood ratios were 2.6 and 0.10, respec-
ively. Performance did not materially improve when only
eversible MPI defects were considered. Logistic regres-
ion analysis revealed a relationship between the percent-
ge stenosis at quantitative coronary angiography and
PI results defined either as any perfusion defect or as a
eversible defect only. Similar results were observed for
oronary CTA-defined stenosis and MPI results. Based
n ROC curve analysis, invasive angiography and coro-
ary CTA results had a similar ability to identify patients
ho would have a defect on MPI. These data were
nterpreted as showing that coronary CTA was as accu-
ate as invasive angiography in identifying patients with
unctionally significant CAD.
Taken together, these studies suggest that MPI and
oronary CTA measure different parameters relevant to
schemic heart disease. Of note, a normal MPI does not
xclude the presence of coronary atherosclerosis, but it does
ignify a very low risk of short- to mid-term adverse cardiac
vents. Conversely, coronary CTA allows detection of
therosclerotic plaques that are not hemodynamically sig-
ificant. The optimal management of such nonobstructive
isease is not established.
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Expert Consensus on CT Angiography June 8, 2010:2663–99.1.3. Comparison of Coronary CT Angiography With
ractional Flow Reserve
hree groups have examined coronary CTA data using
ntracoronary FFR data as the reference standard for hemo-
ynamically significant obstructive disease (64–66). These
ata complement the MPI comparisons described above by
howing that coronary CTA anatomic data do not provide
ery accurate insights into the probability that specific
esions will produce clinically significant ischemia. The
ollowing studies illustrate these points.
A retrospective study from Erasmus University identified
9 patients (mean age 60 years) over a 3-year period (2004
o 2007) who had coronary CTA (either 64-channel or dual
ource) and also had invasive coronary angiography with
FR measurement of a single discrete lesion (59). Patients
ith prior revascularization were excluded. A coronary
tenosis was considered significant if it was 50% or more by
isual assessment or by quantitative measurement. An FFR
alue less than 0.75 was considered functionally significant.
greement between coronary CTA and invasive angiogra-
hy was found in 49% of the 89 lesions of interest. Fifteen
f the 16 lesions significant by FFR were also significant by
oronary CTA. Overestimation by coronary CTA occurred
n 44 lesions. Sensitivity and specificity of coronary CTA for
FR-defined hemodynamically significant lesions were 94%
nd 40%, respectively.
In a prospective study of 81 patients from Belgium,
iagnostic accuracy of coronary CTA judged against func-
ional significance assessed by FFR was fair with a sensitiv-
ty of 79%, specificity of 64%, positive likelihood ratio of
.2, and negative likelihood ratio of 0.3 (65). Decision
aking based on coronary CTA results would have led to
evascularization in patients without ischemia in 22% and
nappropriate deferral in 7%.
.2. Prognostic Evaluation of Coronary CT
ngiography in Stable Patients With
uspected Coronary Disease
he hallmarks of a clinically informative prognostic study
ave been summarized earlier in this document. Due to the
elatively short time interval that has elapsed since the
linical introduction of 64-channel CT scanners, no studies
ave yet been reported with this technology that have
dequate statistical power to test the independent prognos-
ic value of coronary CTA (i.e., using multivariable analysis
ethods). However, Min and colleagues (67) have reported
n the relationship between all-cause mortality and coro-
ary CTA results in 1127 patients using a 16-channel CT.
atients presented with stable symptoms thought to repre-
ent possible obstructive CAD and had coronary CTA as
heir primary diagnostic imaging test. By pretest assessment,
0% were low probability for significant CAD, 50% were
ntermediate probability, and 20% were high probability.
ean follow-up was 16 months. Cumulative survival in the
ow-probability patients was 99%, while that in the pntermediate-probability patients was 97% and in the high-
robability patients was 92%. In multivariable analysis, the
resence of plaque in greater numbers of coronary arteries
long with the severity of stenosis observed and the presence
f plaque in the left main coronary artery were predictors of
ortality. A summary measure of the extent and severity of
AD (a modified Duke Coronary Disease Index) was also
ndependently prognostic. Patients with no detectable
laque by coronary CTA (n333 or 30% of the cohort) had
0.3% mortality rate, indicating that a completely negative
tudy was associated with a very low risk of death over the
ubsequent 15 months.
A study from Harbor-UCLA described the follow-up of
538 patients who underwent coronary CTA by electron-
eam tomography (68). The subjects had a mean age of 59
ears, and 70% were men. Symptom status was not re-
orted. Follow-up averaged 78 months. The extent of
ignificant disease, described as the number of diseased
essels, was a significant prognostic factor beyond conven-
ional risk factor and demographic data. Coronary calcium
dded modest prognostic information to the extent of
AD. While this study has the longest follow-up to date of
he prognostic studies using coronary CTA, several caveats
hould be considered. First, using electron-beam tomogra-
hy provided voxels that were significantly longer in the
-axis (3 mm) than in the x- and y-axes (0.34 mm each).
ow this affected the accuracy of diagnostic classification is
nclear. Second, lack of a complete clinical descriptor set
akes assessment of incremental clinical value subject to
ome residual uncertainty.
A study from 3 centers in Europe enrolled 541 patients
2003 to 2007) with chest pain, a positive stress test, or a
igh risk for CAD (69). Patients had both a coronary CTA
94% with a 64-channel CT system) and a gated-SPECT
PI study within 3 months of each other and no interval
vent between them. Mean age was 59 years, and 59% were
en. Four percent of patients were excluded due to an
ninterpretable CT study, 7% were lost to follow-up, and
% underwent an elective revascularization within 60 days
f imaging and were excluded. The remaining 439 patients
ere followed for a median of 1.8 years and experienced 23
vents (5.2%): 8 deaths (2 cardiac), 8 nonfatal MIs, and 7
ospitalizations for unstable angina. In multivariable anal-
sis, significant obstructive coronary disease with 50% or
reater stenosis added independent prognostic information
o baseline risk factors and MPI results, but any atheroscle-
osis on CT did not. Importantly, both the CT and MPI
esults added significant prognostic information to each
ther. In addition, the presence of noncalcified plaque on
T added independent prognostic information to both CT
tenosis and MPI results. The small number of follow-up
vents in this study and the restricted set of baseline clinical
ariables included in the analyses limit the conclusions that
an be drawn.
Another way to view the outcomes resulting from a
articular clinical strategy employing coronary CTA is to
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he test. However, a proper control group is needed to
efine what would have happened with standard manage-
ent (without coronary CTA). In a study from Ontario of
017 consecutive patients undergoing invasive coronary
ngiography from January 2005 to February 2007, the effect
f introducing a cardiac CT program in February 2006 was
o decrease the frequency of normal invasive studies from
2% before the program to 27% after the program (70). In
academic centers in Alberta without cardiac CT programs,
he normal invasive coronary angiography rate during the
ame period in 11 508 patients remained stable at 30%.
.3. Use of Coronary CT Angiography in the
ssessment of Patients With Acute Chest Pain
he diagnostic accuracy of coronary CTA in patients with
uspected stable obstructive coronary disease (reviewed in
he preceding text) has typically been studied in patients
lready referred for coronary angiography. In contrast, in the
tudies of coronary CTA use in the assessment of acute
hest pain patients in the emergency department, coronary
TA results have often been compared with expert clinical
ssessment of the final diagnosis, using combined clinical
nd marker data. A strength of this literature is the
voidance of the need to study patients preselected for
nvasive angiography. It is notable that 2 studies random-
zed the use of coronary CTA and that several used careful
ethodology to define their study population and assess
linical outcomes (71–73). However, as with the diagnostic
ccuracy literature for coronary CTA, studies in this area are
rimarily single-center reports that describe the findings of
xperienced observers in small numbers of patients.
Investigators from the William Beaumont Hospital ran-
omized low-risk acute chest pain patients to coronary
TA (n99) versus usual standard of care (n98) proto-
ols (72). Low risk was based on the Goldman-Lee algo-
ithm. Coronary CTA patients with minimal disease were
ischarged; those with stenosis greater than 70% underwent
atheterization, whereas cases with intermediate lesions or
ondiagnostic scans underwent stress testing. Outcomes
ncluded safety (freedom from major adverse events over 6
onths), diagnostic efficacy (clinically correct and definitive
iagnosis), and time and cost of care. In the CTA-alone
rm, 67 patients had normal coronary arteries and were sent
ome, while 8 with severe disease were referred for invasive
valuation. The remaining 24 patients required stress test-
ng, owing to intermediate severity lesions or nondiagnostic
cans. Of these, 21 of 24 (88%) had negative stress nuclear
tudies and were discharged. Overall, 88 of 99 (89%)
atients in the coronary CTA arm were discharged home
rom the emergency department. In the usual care arm, 93
f 98 patients (95%) had negative nuclear stress tests and
ere discharged home. Of the remaining 5, 3 had invasive
oronary angiography and 2 were discharged to outpatient
ollow-up. During the index visit, CTA evaluation reduced
iagnostic time compared with standard care (3.4 h versus s5.0 h, p0.001) and lowered costs ($1586 versus $1872;
0.001).
Investigators at Seoul National University randomized
68 acute chest pain patients (mean age 58 years) to
4-channel coronary CTA or conventional care (71). Final
iagnosis of ACS was made in 29% of the study cohort by
cardiologists independently using data from the clinical
ecord 1 month after discharge. Coronary CTA use had no
ffect on the rate of diagnosis of ACS but was associated
ith fewer admissions deemed unnecessary in the interme-
iate probability group and with a decreased hospital length
f stay, which seemed to occur primarily among high-risk
atients. One patient in the conventional strategy had a
onfatal MI by Day 30, while no events occurred out to 30
ays in the coronary CTA strategy.
At Massachusetts General Hospital, the ROMICAT
Rule Out Myocardial Infarction Using Computer Assisted
omography) study prospectively enrolled 368 acute chest
ain patients (39% women, mean age 53 years) with an
nconclusive initial emergency department evaluation (in-
luding an initial ECG without ischemia and a normal
nitial troponin) in a protocol to receive a 64-channel
oronary CTA scan (74). Screening for the study took place
uring weekdays over 2 years (2005 to 2007). Patients with
nown CAD were excluded. All physicians involved in the
anagement of these patients were blinded to the coronary
TA results. Coronary CTA studies were evaluated inde-
endently for the presence of any coronary atherosclerotic
laque, as well as for significant coronary artery stenosis
greater than 50% stenosis) by 2 experienced observers who
ere blinded to all the clinical data. Among the 368 study
atients, 31 (8.4%) were judged to have had ACS. Over a
-month follow-up, none of the patients without ACS had
clinical outcome event. The time required to perform the
T scan averaged 16 minutes from the time of arrival in the
maging room, scans took an average of 14 seconds to
erform, and average interpretation time was 9 minutes. By
oronary CTA, 50% of patients were completely free of
AD, 31% had nonobstructive plaque, and 19% had sig-
ificant obstructive CAD. Comparing the presence of any
oronary plaque with the consensus diagnosis of ACS,
oronary CTA had a sensitivity of 100% and a specificity of
4%, with a positive likelihood ratio of 2.2 and a negative
ikelihood ratio of 0.02. The presence of obstructive CAD
ad a sensitivity of 77% and a specificity of 87% for the
onsensus diagnosis of ACS, with a positive likelihood ratio
f 5.9 and a negative likelihood ratio of 0.3. Of the 34
atients with significant obstructive CAD by CT, 14 were
ot diagnosed as having ACS, and none of these patients
ad a follow-up event out to 6 months.
A prospective study from the University of Pennsylvania
nrolled 586 patients with suspected ACS who had a low
hrombolysis In Myocardial Infarction (TIMI) risk score
nd received a coronary CTA study (75). Four hundred
eventy-six (84%) were discharged home after their CT
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ut to 30 days.
Overall, these results reinforce the data from the stable
ngina studies showing that a negative coronary CTA study
mproves diagnostic certainty for ruling out significant
oronary disease in a low-risk acute coronary population.
.4. Use of Coronary CT Angiography in
reoperative Evaluation of Patients Before
oncoronary Cardiac Surgery
ne potential role for CTA may be for preoperative
valuation of cardiac patients who are referred for noncoro-
ary cardiac surgery. Several small studies have reported
igh diagnostic accuracy in these patients (76–80). The
argest study to date consisted of 70 patients, of whom 31
ad aortic stenosis (44%), 24 had mitral insufficiency (34%),
had aortic insufficiency (13%), and the remainder had
ther valvular or congenital lesions. On a per-patient basis,
ensitivity and specificity were 100% (18 of 18 patients with
ignificant CAD) and 92% (48 of 52 patients without
ignificant CAD), respectively (78). The corresponding
egative likelihood ratio is 0.01, which means a negative test
ould be associated with a very low post-test probability of
isease for patients with low- and intermediate-pretest
robabilities. Assuming that all patients previously would
ave been referred for invasive angiography, coronary CTA
llowed the 48 patients (69%) in the study cohort with
egative CT findings to avoid this procedure. However, a
ositive coronary CTA requires confirmation with invasive
oronary angiography to establish the need for and extent of
ypass surgery.
.5. Use of Coronary CT Angiography in the
ollow-Up of Cardiac Transplant Patients
nother potential application for coronary CTA is the
valuation of the cardiac transplant patient. Most transplant
enters perform “routine” annual coronary angiography
eginning 1 year after surgery, and the majority of these
nnual angiograms are negative. Absence of angiographic
AD is an important predictor of survival without adverse
vents in heart transplant patients (81). However, because of
he diffuse and concentric nature of transplant vasculopathy
82), patients with clinical events often do not have angio-
raphically “significant” disease, and IVUS is the method of
hoice for the detection of angiographically silent plaques in
uch patients (83). In contrast to invasive coronary angiog-
aphy, coronary CTA permits visualization of atheroscle-
otic changes of the vessel wall including those associated
ith transplant vasculopathy. Sixty-four–channel coronary
TA has been tested in 2 small single-center studies (20
atients each), as a possible replacement for “routine”
nnual coronary catheterization with or without IVUS
84,85). Although getting the transplanted heart to the
arget heart rate can be difficult, the study from the
assachusetts General Hospital obtained diagnostic quality
mages in 83% of coronary segments. Sensitivity for identi- pying coronary stenosis or coronary plaque judged by inva-
ive coronary angiography plus IVUS was 70% with a
pecificity of 92% (84).
.6. Use of Coronary CT Angiography in Patients
ith Prior Coronary Bypass Surgery
n general, imaging of vein grafts with coronary CTA is less
hallenging than imaging the native coronary arteries pri-
arily because of their larger size (typically 3 to 4 mm
iameter) and reduced mobility compared with the epicar-
ial coronary vessels and because they usually are not
alcified. Assessment of internal mammary grafts is some-
hat more difficult due to artifacts caused by metal clips and
heir smaller size (1 to 2 mm diameter) (86). Accuracy of
oronary CTA for assessing graft stenosis has been shown to
e somewhat lower than for assessing graft occlusion.
ssessing the adequacy of the distal anastomotic site is more
ifficult than either patency or stenosis of the graft itself,
ue to the frequent presence of calcification and/or clips at
he site and greater motion of this portion of the graft.
If coronary CTA is to supplant the need for invasive
oronary angiography in prior coronary artery bypass graft
urgery (CABG) patients, then it must be able to provide
ccurate information in 4 areas: 1) patency of grafts; 2)
resence of stenoses in grafts; 3) the status of the proximal
nd distal anastomoses; and 4) the presence of significant
esions in the native coronary arteries both downstream
rom the grafts and in ungrafted segments.
In the most recent meta-analysis on the diagnostic
ccuracy of 64-channel coronary CTA, 6 studies were found
through November 2007) involving a total of approxi-
ately 350 CABG patients (50). Coronary CTA was able
o detect complete occlusion of grafts with a sensitivity of
7% and a specificity of 100% (calculated on a per-graft
ather than a per-patient basis). Considering both signifi-
ant stenosis and occlusion, sensitivity was 98% and speci-
city was 97%. The positive likelihood ratio was substan-
ially above 10 with a negative likelihood ratio of 0.02,
ndicating that coronary CTA can rule in or rule out graft
isease with a high degree of certainty in patients with an
ntermediate pretest probability of disease (in the 50%
ange).
Assessing the native coronary arteries distal to the anas-
omosis is significantly more challenging than assessing
rafts since they tend to be small and sometimes heavily
alcified. In a study of 50 post-CABG patients from the
niversity of Erlangen, 9% of all coronary segments in the
ative coronary arteries (either ungrafted arteries or grafted
rteries distal to the graft) were unevaluable, due primarily
o severe calcification or motion artifacts (87). In the
valuable segments, coronary CTA had a sensitivity of 86%
ith a specificity of 76% for significant stenoses. When the
nevaluable segments were classified as diseased, the diag-
ostic accuracy for the detection of significant stenoses was
8%. Although these values reflect an improvement over
revious scanner generations, they are still lower than
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atients without previous bypass surgery. Because chest pain
fter bypass surgery might be associated with new stenosis
f a graft or a native coronary artery, the difficulty of
ccurately assessing the native vessels is an important
imitation for the clinical use of coronary CTA in patients
fter CABG.
From a technical standpoint, there are also differences in
oronary CTA for the post-CABG patient compared to the
atient without grafts. Patients with grafts are routinely
tudied from the level of the aortic arch to the diaphragm,
ompared to the level of the carina in patients who have not
ad prior CABG. In order to fully examine the patient with
nternal mammary grafts, some investigators have suggested
need to cover to the level of the clavicle so that subclavian
tenosis can be ruled out. This increased coverage results in
need for a greater amount of contrast, longer breath hold,
nd greater amount of radiation. With 64-channel scanners,
he longer breath hold is usually clinically insignificant, but
he contrast and radiation increases remain (86).
.7. Use of Coronary CT Angiography in Patients
ith Prior Coronary Stenting
he evaluation of stents by MDCT is significantly more
ifficult than the evaluation of coronary artery segments
ithout stents, even using current generation 64-channel
DCT scanners. At least 3 different types of artifacts may
omplicate the imaging of coronary stents with coronary
TA.
• Motion artifacts are the most common reason in most
series for unassessable stented coronary segments.
These can be seen even with controlled heart rates and
reconstruction techniques designed to optimize tem-
poral resolution. Motion artifacts tend to exacerbate
the other types of artifacts noted here.
• Beam hardening artifacts occur because the metal of the
stent struts absorbs much more of the lower-energy
portion of the X-ray beam than the surrounding soft
tissues. As a result, the X-rays that are not absorbed
and reach the detector array have a higher proportion
of high-energy X-ray photons than expected in the
standard reconstruction algorithms used for cardiac
CT. The result is a “blooming artifact” that causes the
stent struts to appear thicker in reconstructed images
than they actually are. In some cases, the blooming
may extend into the arterial lumen, interfering with
the ability to assess the presence and extent of disease.
Special reconstruction algorithms (called convolution
algorithms or kernels) are now routinely used for
coronary CTA studies in patients with coronary stents
in order to (partially) correct for this beam hardening.
• Partial volume averaging is an artifact that may affect the
voxels immediately adjacent to stent struts. When
individual voxels contain information both from low-
attenuation tissue (coronary artery, noncalcified plaque) iand higher-attenuation coronary stent struts or coro-
nary calcium, the image reconstruction algorithms
assign average HUs to the voxels in question (averag-
ing the higher- and lower-attenuation data into 1
summary attenuation value for that voxel). One result
of this effect can be a loss of the sharp edge delineating
the stent and the lumen. Since partial volume averag-
ing is related to spatial resolution, it tends to be a
greater problem in stents in smaller-diameter artery
segments.
ome insights into the effects of these artifacts on stent
maging with coronary CTA can be obtained from in vitro
tudies, which have the advantage of eliminating some of
he complexities of patient imaging, such as motion. An in
itro study of 68 different stents using 64-channel MDCT
maging found that use of special reconstruction algorithms
mproved visualization of the stent lumen and reduced
looming artifact at the cost of a modest increase in noise in
he images (88). Stent luminal diameter measurements with
lectronic calipers averaged 57% of the true lumen diameter,
ith the best results (from an imaging perspective) at about
0% of true diameter. Different stent compositions and
tructures appeared to be associated with variations in the
xtent of residual artifact, suggesting that stents cannot all
e regarded as equivalent in evaluating diagnostic coronary
TA performance. Similar results from the same group
ere obtained studying 29 different stent types using dual-
ource CT (89). A second in vitro study examined the effect
f different amounts of in-stent stenosis and vessel diameter
n 64-channel MDCT results (90). All 4 stents studied
ere associated with some blooming artifact leading to
nderestimation of the true stent diameter. Of vessels 3-mm
r greater, no nonstenotic or low-grade stenotic vessel was
isdiagnosed as an intermediate- or high-grade stenosis.
In the most recent meta-analysis of 64-channel coronary
TA covering studies published through September 2008,
4 studies of patients with prior coronary stenting were
dentified (91). In this relatively small, highly selected
opulation, the prevalence of in-stent restenosis (greater
han 50% diameter) was 20%, and pooled data showed a
ensitivity of 90% and a specificity of 91% when only
ssessable segments were considered. In 5 studies where the
onassessable segments could also be included, sensitivity
as 79% with specificity 81%.
The criteria for assessing the quality of stent images and
he willingness to interpret images with some artifact
vidence likely vary among investigative groups. In 1 careful
tudy from the Massachusetts General Hospital, coronary
TA images of 54 stents in 44 patients were graded for
mage quality by 2 independent observers (92). A 64-
hannel MDCT scanner was used, and image reconstruc-
ion employed an algorithm known to reduce beam-
ardening artifacts. Thirty of 54 stents (56%) were judged
ssessable by virtue of being free from major lumen distort-
ng artifacts. Stent size was an important determinant of the
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Expert Consensus on CT Angiography June 8, 2010:2663–99esults. Stents 3.5 mm or larger (100%) were judged
ssessable; 80% of 3 mm and 33% of stents smaller than
mm were judged assessable. The major limits to assess-
bility were partial volume averaging and beam hardening
ffects.
Thus, in a patient known to have larger stents and whose
linical presentation suggests low-to-intermediate probabil-
ty for restenosis, 64-channel coronary CTA may be a
easonable alternative to invasive angiography to rule out
ignificant in-stent restenosis, presuming high image quality
an be obtained. Further research will be needed to validate
he diagnostic accuracy data from the most recent 64-
hannel coronary CTA studies and to examine additional
otential determinants of diagnostic accuracy, such as gen-
er and diabetes, which can influence stent size and prob-
bility of restenosis. Some of the concepts suggested by in
itro studies related to variations in diagnostic performance
mong different individual stents will require validation in
uch larger studies than have been performed to date. In
ddition, outcome studies are needed that evaluate strategies
f coronary CTA use and their influence on downstream
esting and therapy.
.8. Other Patient Subgroup Data
ther specific populations of interest that have been re-
orted on include women, patients with left bundle-branch
lock, patients with LV dysfunction of possible ischemic
tiology, and patients with atrial fibrillation. In each case,
reliminary data are available in the form of 1 or several
tudies, each from a single center, using patients referred for
nvasive angiography.
Three studies have examined the diagnostic performance
f 64-channel coronary CTA in women versus men (93–95).
he Leiden study of 52 women and 51 men found no
ifference in accuracy, while the Rotterdam study in 123
omen and 279 men found similar overall sensitivities but
ower specificities in women (94,95). However, in the
er-segment analysis, sensitivities in women were lower in
he distal segments and side branches compared with those
een in men (94). A third study from Humboldt University
n Berlin of 50 women and 95 men reported a lower overall
ensitivity for women (70% versus 95% for men) and a
igher rate of nondiagnostic examinations (14% versus 4%
or men), due at least in part to the smaller size of coronary
rteries in women (93).
Noninvasive stress tests have reduced accuracy in patients
ith left bundle-branch block, and invasive angiography is
ften required to clarify an uncertain diagnosis. An initial
tudy of the diagnostic accuracy of 64-detector scanning has
een reported in 66 patients with complete left bundle-
ranch block (mean age 69 years) admitted for invasive
oronary angiography (96). Significant coronary disease,
efined as greater than 50% diameter stenosis, was found in
4%. No coronary CTA study was excluded from analysis.
T correctly identified 35 of 37 (95%) patients withoutignificant stenosis and 28 of 29 (97%) patients with dignificant stenosis on invasive coronary angiography. On a
er-vessel basis, specificity was high but sensitivity was low
or the circumflex (59%) and the right coronary artery
52%).
The performance of 64-channel coronary CTA in pa-
ients with dilated cardiomyopathy of uncertain etiology has
een studied in 93 patients (mean age 65 years) who were
eferred for invasive catheterization (97). Significant coro-
ary disease was defined as greater than 50% stenosis in 2
rthogonal views using quantitative coronary angiography.
he prevalence of coronary disease was 46%, and 33% of the
ohort were felt to have ischemic heart failure. Patients with
ingle-vessel disease were considered nonischemic unless
he lesion was in the left main or proximal anterior-
escending artery. No patient was excluded from analysis.
oronary CTA correctly identified 92% of patients without
AD and 98% of patients with CAD. All patients with left
ain or 3-vessel disease were correctly identified. Coronary
TA also correctly identified 97% of patients without and
0% of patients with ischemic heart failure.
Atrial fibrillation poses a particular challenge to coronary
TA imaging for 2 main reasons: because heart rates are
ypically higher than 60 beats per minute, and because R to
intervals are irregular. Higher heart rates require use of a
T with very high temporal resolution in order to capture
he coronary images without motion-related blurring, while
rregular R to R intervals makes the use of data from more
han 1 cardiac cycle in the image reconstruction process
ubject to misregistration errors. One small study has
eported on an initial experience of coronary CTA in 15
atients (mean age 58 years) with atrial fibrillation and
uspected coronary disease referred for invasive angiography
98). Imaging was done with a 64-channel dual-source CT,
hich provides a nominal temporal resolution of about one
ourth of a gantry rotation or about 83 milliseconds. The
ean heart rate during imaging of the study cohort was 84
lus or minus 9 beats per minute. Of 225 segments, 6% to
% were judged to be of too-poor quality to be interpreted,
rimarily due to residual cardiac motion. Imaging of the
eart in a single cardiac cycle, recently demonstrated to be
easible with 256-detector scanners, could theoretically elimi-
ate the need for stable heart rhythms during scanning (99).
.9. Assessment of Global and Regional
eft Ventricular Function
he literature on the assessment of LV function using
ardiac CTA in patients with suspected or known CAD is
uch smaller than that reviewed earlier in this document for
iagnostic coronary imaging. One likely reason is that
chocardiography already provides a readily available, non-
nvasive means of assessing ventricular function and wall
otion and does so without exposing patients to ionizing
adiation or iodinated contrast agents.
To create the images needed for assessment of ventricular
unction with retrospectively gated CTA studies, axial
atasets are typically reconstructed at 5% to 10% increments
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyhrough the R to R interval. This provides a 4D volumetric
ataset for analysis that can be viewed as a cine loop in the
tandard views, including 2- and 4-chamber views and
hort-axis views. Ejection fraction can be estimated visually
r quantitatively using tracings of the ventricular chamber in
iastole and systole.
The only meta-analysis to date covered publications
hrough March 2006 and found only 4- and 16-channel
TA comparisons with CMR. These studies involved a
otal of 252 patients (100). Assessment of the left ventricle
y CTA was performed using short-axis cine images that
panned the length of the entire LV, as is customary with
MR. The difference between LV ejection fraction mea-
ured with CMR and with CTA averaged 1.7% (CTA
ean 52.9% versus CMR 54.6%). For the subset of studies
sing 16-channel machines, the difference was less than 1%.
More recent comparisons of 64-channel coronary CTA
nd CMR have confirmed the results of these earlier studies
howing the close correlation of ejection fraction measured
y these 2 techniques. In a retrospective study of 63 patients
rom Kyoto University who had the 2 studies within 2 weeks
f each other, the mean ejection fraction difference was
.224.2% (r0.97) (101).
A study from Massachusetts General Hospital compared
4-channel CTA with 2D echo and with SPECT estimates
f LV ejection fraction (102). Thirty-six patients had
ardiac CTA and echo or SPECT imaging within 3
onths. The overall correlation between CT and the other
imaging modes was very good (5715% versus 5813%,
0.86) with the strongest correlation between CT and
PECT (r0.90). A separate study from the same institu-
ion examined correlations between 64-channel CT and 2D
cho in 25 patients with ejection fractions less than 45%
ho had both tests within 4 weeks (103). Ejection fraction
y CT was 3812% versus 368% for echo (r0.67).
egional wall motion was assessed using a 17-segment
odel with a 4-point scale and showed modest agreement
kappa0.61).
. Emerging Applications
opics included in this section are those for which the data
re not yet deemed sufficient to support development of
onsensus opinions.
.1. Noncalcified Coronary Plaque Imaging and
ts Potential Clinical Uses
everal imaging technologies have been used to study
theroma progression or regression during life in patients.
VUS has been used in coronary arteries (104–110), exter-
al ultrasound has been used to measure carotid intimal
edial thickness (111), and magnetic resonance has mea-
ured aortic and carotid atheroma (112). In each instance,
erial imaging has been capable of measuring statistically
ignificant change over time in atheroma burden as well as eifferential responses between active treatment and control
opulations. Given the ability of coronary CTA to image
he coronary arterial wall, it may be possible to use this test
o monitor atheroma burden over time. At present, such
pplications are considered of uncertain clinical utility and
ave been limited to research uses.
.2. Assessing Atherosclerotic Burden
n order to detect changes in atherosclerotic burden over
ime, it is necessary to be able to accurately define the
resence and extent of disease in each segment of the
oronary tree. A meta-analysis of coronary CTA detection
f coronary plaque in comparison with IVUS covering
ublications through April 2008 found 14 studies involving
40 patients (113). Sensitivity of coronary CTA on the
esion level averaged about 90%, while per-segment sensi-
ivity was lower at 81% to 86%. At the vessel level, coronary
TA was more sensitive for calcified plaque than noncal-
ified plaque. This literature has a number of important
imitations, including the small sample and the fact that
VUS is performed only in selected arteries usually to clarify
he significance of an intermediate lesion. A full comparison
f IVUS and coronary CTA data in all segments is unlikely
o be feasible.
Comparison of coronary CTA and histology in post-
ortem coronary artery specimens has shown that the
therosclerotic plaques themselves undergo variable en-
ancement after contrast injection (114). While calcified
nd noncalcified plaques can be differentiated by CT, persua-
ive evidence supporting reliable subclassification of noncalci-
ed plaques as lipid-rich versus fibrous-based on CT attenu-
tion numbers is not currently available (25,115–121). If
ifferences in plaque density could be reliably measured,
uch measures could be used to monitor treatment-induced
r natural progression and regression of coronary atheroma
122,123).
Quantifying plaque burden with coronary CTA has also
roven difficult. The primary limitations include accurate
efinition of the adventitial border, spatial resolution (cur-
ently approximately 0.4 mm), and artifacts created by
alcified atheroma. At present, coronary CTA is best suited
or analysis of plaque burden in the larger proximal coronary
egments.
A few examples can serve to illustrate the current state of
esearch in this area. In a study from the University of
rlangen of 41 patients who underwent 64-channel coro-
ary CTA and were found to have only noncalcified
laques, 2 independent observers calculated the volume of
laque in proximal coronary segments (124). Interobserver
ariability of these measurements varied significantly by
rtery, with the lowest variability in the LAD (1710%)
nd the greatest in the circumflex (3213%). In the LAD,
he average volume of atheroma was 150 mm3. There was a
ignificant inverse correlation between plaque volume and
ariability. In addition, studies with higher image quality
xhibited less variability in measurement of plaque.
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Expert Consensus on CT Angiography June 8, 2010:2663–99In a follow-up investigation from this same group, 50
atients with single noncalcified atherosclerotic lesions of
he left main or proximal LAD artery who had a previous
4-channel coronary CTA had a follow-up research coro-
ary CTA done at least 12 months after the first one using
he same methods (125). Only patients with ideal baseline
mages were selected for study. Two independent readers
nalyzed CT datasets in random order. Readers were
linded to each other’s readings as well as to clinical
nformation and to information about whether the study
as baseline or follow-up. Plaque areas were manually
raced in serial 1-mm sections and the total volume of
laque was calculated by multiplying area by reconstruction
ncrement (which yielded the height or depth of the lesion).
he difference in volume between the second and the first
can was divided by the interval in years between the 2 scans
o yield the annualized rate of change. Mean time to the
econd scan was 16.8 months. Mean interobserver variabil-
ty was 1612%, confirming the investigators’ earlier work
hat LAD and left main artery images gave reasonably
eproducible estimates for plaque volume. The mean non-
alcified plaque volume in the 50-patient sample increased
rom 9281 mm3 on baseline scans to 115110 mm3 at
ollow-up, representing a mean annualized progression rate
f 22%. Eighty-four percent of patients showed progression,
hile 16% showed regression. Neither the baseline plaque
olume nor the baseline low-density lipoprotein (LDL) or
igh-density lipoprotein levels nor the use of statins ap-
eared to have any influence on the rate of progression. The
eneralizability of these findings from this very select group
f patients is unclear, but the fact that the 50-patient sample
as chosen from a parent cohort of 1134 consecutive
oronary CTA patients indicates that much more work will
e needed to prove these methods are ready for general
linical use.
Several pilot studies have used coronary CTA to study
reatment effects on atheroma. Investigators from Chiba
niversity studied 21 patients with 16-detector CT before
nd after 1 year of treatment with atorvastatin 10 mg daily
126). One noncalcified plaque was followed for each
atient. No significant change in atheroma area was seen
fter treatment, during which mean LDL cholesterol fell
rom 122 mg/dL to 96 mg/dL. There was, however, a
ignificant (but weak) direct correlation between the final
DL cholesterol level and the degree of plaque area change
r0.39, p0.05). Additionally, the average density (as-
essed by HU) in the studied plaque increased significantly
ver the treatment period, suggesting the possibility of a
avorable alteration in plaque composition.
.3. Identification of Vulnerable Plaques
n addition to atherosclerotic burden, some initial investi-
ations have been performed to evaluate the ability of
oronary CTA to identify “vulnerable” plaques based on
heir apparent composition. In 1 small study from Beijing of
6 patients who underwent 64-channel MDCT and IVUS, flaque analysis software using HU ranges was not able to
istinguish between lipid-rich and fibrous plaques (127). In
study from Hiroshima University, 21 patients had 64-
hannel coronary CTA and IVUS studies focusing on 38
oncalcified lesions (128). The mean CT density of hypo-
choic lesions was significantly lower than that of hyper-
choic lesions. There was also good agreement between the
tests in the amount of calcium evident in the plaques.
An investigation of 50 patients (25 stable, 25 with ACS)
rom Leiden University compared 64-channel MDCT
laque composition (noncalcified versus mixed versus com-
letely calcified) with virtual histology IVUS (129). On
oronary CTA, 32% of plaques in ACS patients were
oncalcified and 59% were mixed. In stable CAD patients,
1% of plaques were completely calcified. In virtual histol-
gy IVUS, several features suggesting vulnerable plaque
omposition were more prevalent in the ACS patients. On
oth coronary CTA and IVUS, composition of culprit and
onculprit plaques appeared identical.
.4. Left Ventricular Enhancement Patterns
everal studies have used MDCT to evaluate the LV
yocardium in patients with prior MI. A retrospective
tudy of 202 patients (6313 years) attempted to detect
revious MI in patients referred for 64-channel coronary
TA (130). Significant differences were noted between
ttenuation values of infarcted versus normal myocardium
5623 HU versus 12419 HU, p0.01). Thinning of
yocardial walls was noted only in chronic MIs (p0.01).
MDCT has also been evaluated for the prediction of
mprovement in LV parameters after MI. In one such study,
6 patients (539 years) underwent MDCT and TTE
ithin 1 week of acute MI, with a follow-up TTE at 3
onths (131). MDCT evaluation examined early perfusion
efects (ED) as well as delayed enhancement (DE). In
yocardial segments considered abnormal by TTE, both
D and DE were associated with nonrecovery. Conversely,
yocardial segments with lower prevalence of ED and DE
ere associated with recovery as assessed by TTE.
0. Areas Without Consensus
he 3 topics included in this section (incidental extracardiac
ndings, use in asymptomatic high-risk individuals, and the
triple rule-out” in the emergency department) have been
he subject of some empirical research, but the data overall
re not yet sufficiently clear to support the development of a
onsensus.
0.1. Incidental Extracardiac Findings
he literature describing the prevalence of extracardiac
bnormalities in cardiac CT studies, the extent of their
linical significance, and the impact on patient health
emains insufficient to answer the important clinical and
olicy questions raised by this aspect of the test’s use. In the
ew published studies, there is considerable variation in how
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyncidental findings are categorized, and the specific defini-
ion applied to a “clinically significant finding,” ranging
rom one that requires follow-up or clinical correlation to
ne that needs immediate evaluation or treatment. Data are
ven scarcer concerning the clinical implications of these
ncidental findings, with only 5 studies reporting on thera-
eutic consequences after short-term follow-up (132–136).
o data are available documenting the impact these inci-
ental findings have on long-term patient outcome, the
osts associated with additional evaluations and treatments,
r potential increased anxiety caused for the patient and
hysician.
Extracardiac findings detected with cardiac CT have an
verall prevalence ranging from 20% to 53% of cases using
lectron-beam CT (134,137) and 15% to 67% of cases using
DCT (132,133,136,138–141). Considering the broad use
f the term “clinically significant finding” in the studies to
ate, a more informative classification of incidental findings
ould be as follows: 1) benign finding: no clinical impor-
ance, requiring no additional work-up or follow-up; and 2)
linically significant finding: potentially or definitely impor-
ant lesion requiring additional investigation. This second
ategory can be subdivided into indeterminate findings
equiring clinical correlation or follow-up, and major find-
ngs requiring immediate evaluation or management. Using
his classification, approximately 4% to 25% of findings are
eported to be potentially significant, requiring clinical
orrelation or follow-up, and 5% to 11% are reported to be
ajor, requiring immediate evaluation or intervention.
Opinions vary greatly as to the importance of routinely
eporting noncardiac findings in a coronary CTA study, in
arge part because of the deficiencies in empirical outcome
nd cost data (142). Some have argued that reporting of
oncardiac findings would lead to additional costs and
nxiety to the patient without proven benefit (143). Those
olding such opinions may use filters to reduce the “maxi-
um” field of view allowable, which limits the amount
f mediastinum, lung, breast, and other thoracic structures
hat are reconstructed, although it does not completely
xclude such structures. Others advocate reconstructing the
xamination with a full field of view to identify all inciden-
al findings and report on their clinical significance
133,140,144). They point out that CT differs from the
ther cardiac imaging modalities by providing high-
esolution diagnostic information about other organs be-
ides the heart, with no extra radiation to the patient.
oreover, for symptomatic patients, typically with chest
ain or shortness of breath, and an intermediate or high
retest probability of a noncardiac cause of the symptoms,
xtracardiac findings may not be “incidental.”
In a series of 254 patients from Seoul who underwent
oronary CTA, a noncontrast low-dose whole thoracic scan
as used to screen for unrecognized extracardiac lesions
145). The coronary CT study was then reconstructed with
small field of view. In 20% of patients, an extracardiacbnormality was found on the initial thoracic scan that cequired additional work-up, treatment, or follow-up, while
uch findings were noted in 2% of patients from the contrast
oronary CT study.
In the prospective ROMICAT study involving 395 acute
hest pain patients presenting to the Massachusetts General
ospital Emergency Department, 45% of the patients had
or more incidental findings with 19% having 2 or more
uch findings (135). Noncalcified pulmonary nodules were
ost common (24%), followed by liver cysts (7%) and
alcified pulmonary nodules (4%). Adjudication by an out-
omes committee determined that 1.3% of patients (n5)
ad their management changed by the incidental finding
pneumonia, pneumothorax, gallstones). An additional 4%
ere felt to have findings with the potential to alter future
anagement (including hiatal hernia and thoracic aortic
neurysm). Further diagnostic imaging studies were recom-
ended for 21% of patients (n81), including those with
oncalcified pulmonary nodules, contrast-enhancing liver
esions, and mediastinal lymph nodes. At 6 months, 3
atients had received biopsies as a result of the initial
ncidental CT finding, and in 2 patients, cancer was
iagnosed and successfully removed.
Of specific concern with cardiac MDCT is the problem
f incidental noncalcified pulmonary nodules. While sub-
tantial data are emerging from lung cancer screening
tudies of high-risk populations, the populations referred for
ardiac CT are different, and caution should be used in
xtrapolating results of lung cancer screening trials to
ardiac CT scanning. The reported prevalence of indeter-
inate pulmonary nodules discovered at cardiac CT that
rompted radiological follow-up is reported to range be-
ween 1% and 20%. In the study of cardiac CT scans by
numa et al. (136), for the 61 noncalcified lung nodules
dentified, 33 patients went on to have further investiga-
ions, and 2 of the nodules were found to be malignant after
-month follow-up. In the ROMICAT study discussed in
he preceding text, 245 of 395 patients had incidental
ndings of noncalcified pulmonary nodules, and 1 biopsy
as done within 6 months, revealing adenocarcinoma (135).
ollow-up data are not available for the other studies.
verall, the prevalence of indeterminate nodules found at
ardiac CT is much lower than the reported prevalence of
oncalcified lung nodules in high-risk lung cancer screening
opulations. Guidelines for management of small pulmo-
ary nodules detected on CT have been published (146).
The 2008 revision of the cardiology fellowship training
uidelines recommends that level 2 and 3 training include
he review of 150 cardiac CT cases for incidental findings
nd a review of a dedicated teaching file of 25 cardiac CT
ases featuring the presence of significant noncardiac pa-
hology (147). Although this experience serves as an intro-
uction to the topic, it cannot provide expertise in recog-
izing the full spectrum of pathology that can be found in
he thorax outside the heart and in the regions of the upper
bdomen that may be seen in some studies. In the worst
ase, the interpretation of noncardiac structures by physi-
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Expert Consensus on CT Angiography June 8, 2010:2663–99ians without training in cross-sectional imaging of the
horax could lead to missed diagnoses that have immediate
onsequences on patient health; alternatively, it may result
n increased and unnecessary follow-up and referral for
nsignificant findings that have been misinterpreted.
0.2. Use of Coronary CT Angiography in
symptomatic High-Risk Individuals
or many individuals, the process of atherosclerotic plaque
ormation in coronary arteries begins early in life (148).
utopsy studies of young adults dying from traffic accidents,
omicides, and suicides have found that 60% between the
ges of 30 and 39 years have LAD plaques of AHA grade
or higher (fatty streaks and more advanced lesions) (149).
urthermore, those younger individuals with multiple risk
actors have a higher subsequent rate of atherosclerotic
nvolvement (150). Developing an accurate method of
dentifying younger asymptomatic patients with early ath-
rosclerosis who might benefit from intensified risk factor
odification to prevent or retard the onset of clinical disease
epresents an intuitively sensible response to such observa-
ions. Currently, the Framingham risk score (FRS) is often
sed for this purpose (151).
The FRS may not adequately assess risk for patients with
nusually powerful comorbid conditions, such as peripheral
rterial disease, long-standing or difficult to control diabe-
es, chronic kidney disease, smokers, and those with a family
istory of premature CAD. Additionally, young women,
articularly those with early menopause, autoimmune dis-
rders, or poorly controlled hypertension or hyperlipidemia,
ay be misclassified by traditional FRS assessment. A
umber of recent publications have suggested that it is
ossible to use calcium scoring, derived from noncontrasted
T scans of the heart, to improve risk stratification beyond
he information provided by the FRS, particularly for
atients who are in the Framingham intermediate risk
roup (i.e., FRS predicted 8-year risk of coronary heart
isease death of 10% to 20%) (152).
Although current 64-channel coronary CTA can clearly
etect calcified plaques as effectively as electron beam
omographic imaging, it adds the capability to image the
oncalcified plaque, as discussed earlier in this document.
hat is lacking at present, however, is evidence specifically
inking noncalcified plaques that are not obstructive with an
ndependent clinically important increase in risk. In the
arge follow-up studies of coronary calcium in asymptomatic
ubjects, patients without significant calcium (which would
nclude the patients with noncalcified plaques) had a very
ow event rate. In the St. Francis Heart study, this rate was
round 0.1% per year (153).
Investigators from Seoul National University followed
000 middle-age asymptomatic subjects (mean age 50 years)
ho were self-referred for 64-channel coronary CTA for a
ean of 17 months (range 12 to 21 months, 97% complete)
154). Five percent of subjects had a stenosis greater than
0%, and 2% had a stenosis greater than 70%. Almost three fuarters of these individuals had single-vessel obstructive
isease with the lesions most often in the LAD artery. Four
ercent of subjects had only noncalcified plaques with 5 of
0 having a stenosis greater than 70%. In follow-up, the
verall cohort had no cardiac deaths, 1 patient with unstable
ngina required hospitalization, and 14 patients were revas-
ularized, the majority of which resulted from the coronary
TA findings. The prevalence of incidental noncardiac
ndings in this cohort and the additional tests and therapies
hat resulted from those findings were not reported.
To date there are no published trials evaluating the
mpact of specific therapy on clinical outcome in asymp-
omatic subjects identified as having only noncalcified ath-
roma by coronary CTA.
0.3. The “Triple Rule-Out” in the
mergency Department
he use of coronary CTA for the evaluation of patients with
hest pain in the emergency department offers the potential
o assess not only coronary artery stenoses as the cause of
hest pain but also 2 other potentially life-threatening
onditions: acute aortic syndromes and pulmonary embo-
ism. Acute aortic syndromes include aortic dissection,
ntramural hematoma, and rupturing thoracic aortic aneu-
ysm. This so-called “triple rule-out,” however, poses spe-
ific logistic and conceptual challenges. The confidence and
ccuracy with which the pulmonary artery, aorta, and
oronary arteries can be assessed by CT is related to the
uality of contrast enhancement of each of these structures
155,156). The quality of contrast enhancement is, among
ther procedural issues, critically dependent on the timing
f scanning relative to the beginning of contrast-medium
njection (scan delay). Intravenously administered contrast
aterial typically provides adequate opacification of the
ulmonary arteries 8 to 12 seconds after the beginning of
ontrast injection, while opacification of the ascending aorta
nd coronary arteries occurs 8 to 10 seconds later.
An important challenge of the “triple rule-out” consists of
chieving and maintaining adequate opacification of all 3
ascular beds of interest simultaneously while scanning
roceeds between the apices of the lungs and the diaphragm
ver approximately 15 to 20 seconds with contemporary
canners (157). To avoid respiratory motion artifacts during
canning of the heart due to prolonged breath hold, scan-
ing in the caudocranial direction may be preferable over
he craniocaudal scanning typically used for coronary CTA
157,158). The needed field of view, section thickness, and
can length in the z-axis are different for the small-caliber
nd short coronary arteries than for the comparatively
arge-caliber and long pulmonary arteries and aorta. In fact,
n the setting of an acute aortic syndrome, imaging of the
bdominal aorta and iliac arteries together with the thoracic
orta is necessary for the recognition and characterization of
ritical malperfusion syndromes due to insufficient blood
upply to the lower extremities and abdominal viscera and
or the recognition of aortoiliac occlusive or aneurysmal
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June 8, 2010:2663–99 Expert Consensus on CT Angiographyisease that might complicate the delivery of endografts
ndicated in the treatment of some aortic lesions (159). An
ppropriate scanning protocol for the “triple rule-out” will
herefore represent a compromise between the optimal scan
arameters for each component of the exam (158).
Subsequent image reconstruction from projection data
enefits from ECG triggering or gating for the thoracic
orta and coronary arteries territories (159,160). The ben-
fits and limitations of ECG gating have not been estab-
ished for pulmonary artery CTA. However, the optimal
eld of view is smaller for the coronary arteries than for the
ulmonary arteries and thoracic aorta. Also, the optimal
ime point during the cardiac cycle may vary substantially
ith heart rate for the coronary arteries, whereas the optimal
iming relative to the cardiac cycle for reconstruction of the
horacic aorta is less narrow (160). More than 1 set of image
econstructions may be needed to optimally evaluate the
horacic aorta and the coronary arteries.
Only 2 studies to date have examined the use of CT to
ule out more than 1 possible etiology of chest pain
imultaneously in patients presenting to the emergency
epartment (161,162). In the larger of the 2, from Thomas
efferson University Hospital, all patients qualifying clini-
ally for a “triple rule-out” in the emergency department one
-hour day a week over a 1-year period were prospectively
nrolled. Research assistants present in the emergency
epartment during each enrollment day collected pretest
linical data. Scanning was done with a 64-channel CT
rom the lower margin of the clavicles to the estimated
ower border of the heart (based on scout films) plus a 2-cm
afety margin. Scan length was typically between 17 and 24
m, and scans took between 12 and 15 seconds. The
nvestigators used a 2-phase contrast injection: 70 mL of
ontrast followed by 25 mL of contrast mixed with an equal
olume of saline, all injected at 5 mL/s. The objective was
o visualize the coronary arteries with the undiluted contrast
njection while simultaneously visualizing the pulmonary
rteries with the dilute contrast from the second phase of
he injection. A single experienced radiologist interpreted all
he studies. Severe coronary stenosis was defined as greater
han 70% luminal diameter narrowing. Two independent
hysicians defined final 30-day outcome using the clinical
ecord plus follow-up contacts (98% complete). Of the 201
atients enrolled, 197 completed the protocol. Mean age
as 49 years, 55% were women, and 46% were black.
aseline TIMI risk scores were 0 to 2 in 94% of patients.
iagnostic quality scans of the pulmonary arteries and aorta
ere obtained in 100% of patients. A clinically important
xtracoronary diagnosis that was felt to explain the patient’s
ymptoms was found in 11%, including pulmonary embo-
ism in 3 patients, aortic dissection in 1 patient, and
neumonia in 5 patients. Ten percent of patients had
uboptimal image quality in at least 1 coronary artery. Most
atients had minimal or no disease (88%), while 11% were
ound to have moderate-to-severe disease. For patients with
o significant coronary disease, the post-test probability of eCS was less than 1%. One false-negative study was the
esult of observer error. No adverse outcomes were observed
o 30 days. The mean effective radiation dose was estimated
o be 18 mSv in patients without dose modulation and 8.7
Sv with prospective dose modulation.
Retrospective analysis of 64-channel coronary CTA data-
ets from 50 patients admitted to the emergency department
ith suspected ACS showed that a dedicated coronary CT
rotocol provides excellent visualization of the coronary
rteries and proximal ascending aorta but did not show the
ulmonary arterial system well enough to exclude pulmo-
ary embolism (163).
The volume of contrast material required for a “triple-rule
ut” protocol exceeds the contrast volume that would be
eeded to examine any of the 3 vascular beds separately
157,158). In addition, a “triple rule-out” scanning protocol
ill have a higher radiation dose than typical chest CT or
oronary CTA studies because of the section overlap needed
o allow retrospective gating and the longer scan length.
adiation exposure is increased further when considering
maging of the legs to exclude deep venous thrombosis or
maging of the abdomen and pelvis when assessing an acute
ortic syndrome. This is relevant because some of the
atients with chest pain in the emergency department may
e exposed to more ionizing radiation in the course of their
ork-up if radionuclide MPI or invasive coronary angiog-
aphy is performed subsequently. In the Thomas Jefferson
niversity Hospital study described in the preceding text,
1% of the “triple rule-out” protocol patients had subse-
uent stress MPI studies, and 7% had invasive angiography
162).
The occurrence of acute aortic syndromes or pulmonary
mbolism in the absence of suggestive symptoms and
linical context is uncommon (164), and emergency depart-
ent physicians are usually not uncertain about all 3
ardiovascular conditions examined by the “triple rule-out”
165). Thus, routine use of a “triple rule-out” CT scan
hould not be used as a substitute for a careful clinical
valuation with targeted testing for the most likely causes of
he patient’s symptoms.
1. Safety Considerations
he 2 safety issues involved in use of coronary CTA are
elated to the dose of radiation delivered during imaging
nd the need to use iodinated contrast material. These risks
ill be briefly reviewed in this section.
1.1. Patient Radiation Dose
he typical doses of radiation reported to be associated with
oronary CTA exceed those reported for invasive coronary
ngiography (Table 4).
Although substantial efforts have been directed toward
educing the radiation dose of CTA, most radiation safety
xperts subscribe to a model, discussed in the following text,
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Expert Consensus on CT Angiography June 8, 2010:2663–99hich assumes that there is no safe dose of radiation and any
xposure may increase the long-term risk of cancer. While
uch an assumption represents a “worst-case scenario,” in
rder to minimize any future risk of cancer, it is reasonable
o limit a patient’s exposure to radiation by following some
asic principles, including:
. Ordering coronary CTA only in keeping with estab-
lished appropriateness criteria for cardiac CT and CMR
(1), and only if the clinical question at hand cannot be
adequately addressed by other means (an update of
appropriate use criteria for cardiac CT is expected in
2010 and an update of appropriate use criteria for CMR
is planned).
. Performing the CTA study with the minimum radiation
dose required for adequate diagnostic quality.
. Avoiding unnecessarily repeating coronary CTA.
arameters of absorbed radiation dose, expressed in SI units
f milliGray (mGy), reflect the energy absorbed by the body
f a patient exposed to ionizing radiation (169). The
adiation dose absorbed by patients cannot be measured
asily. The effective radiation dose (E, expressed in units of
illisieverts [mSv]) is the dose parameter most frequently
uoted in the coronary CTA literature. E is a calculated, not
easured, quantity meant to express the risk of a nonuni-
orm partial-body exposure to radiation, for example of the
hest, in patients undergoing coronary CTA, relative to the
hole-body exposure to radiation experienced by Japanese
urvivors of atomic bomb explosions. Estimates of E are
ased on complex assumptions and simulations. They per-
ain to a generic mathematical model of a human body with
mass of 70 kg. The concept of E was developed for the
urpose of radiation protection and cannot (and was never
able 4. Representative Values and Ranges of Effective Dose E
Examination
Representative Effec
Dose Value (mSv)
hest X-ray PA and lateral 0.1
iagnostic invasive coronary angiogram 7
4-slice coronary CTA*
Without tube current modulation 15
With tube current modulation 9
rospectively triggered coronary CTA* 3
ercutaneous coronary intervention or
radiofrequency ablation
15
yocardial perfusion study
Sestamibi (1-day) stress/rest 12
Tetrofosmin (1-day) stress/rest 10
Thallium stress/redistribution 29
Rubidium-82 rest/stress 10
yocardial viability study
PET F-18 FDG 14
Thallium stress/reinjection 41
dapted from Mettler et al. (166) and Strauss and Bailey (167). *64-slice multidetector-row co
CTA indicates computed tomographic angiography; FDG, fluorodeoxyglucose; MBq, megabe
omography.eant to) reflect individualized patient dose. As a rough, weneric estimate of risk, E is mostly useful for comparing
ifferent imaging procedures or protocols and for optimiz-
ng protocols that involve exposure of multiple organ
ystems.
The numerical value of E for coronary CTA can differ
epending on the method used to estimate E even though
he radiation exposure is the same (170–172), and the values
f E reported for coronary CTA in the medical literature
uring different eras may not be comparable to each other.
Because of the uncertainties related to the estimation of
, and because there is no measurable reference standard, E
hould be reported as ranges and not as single numerical
alues. Differences of estimates of E by a factor of less than
are unlikely to be clinically relevant. The range of E
eported for coronary CTA in the medical literature as of
008 is approximately 2 to 32 mSv (166), and the repre-
entative median value of E for coronary CTA with current
echnology is approximately 2 to 15 mSv, with the lowest
alues coming from centers using 64-channel dual-source
T in the “step and shoot” mode (173,174). The ranges and
epresentative medians for E of other common imaging
tudies that use ionizing radiation are listed in Table 4.
The PROTECTION I (Prospective Multicenter Study
n Radiation Dose Estimates of Cardiac CTA In Daily
ractice) trial studied the estimated radiation dose associ-
ted with coronary CTA at 50 international study sites (21
niversity, 29 community) in 2007 (5). The median effective
adiation dose was 12 mSv (interquartile range among
enters 8 to 18 mSv, range 5 to 30 mSv). Small relative
ifferences in estimated radiation dose were correlated with
atient-related factors (patient weight, absence of sinus
hythm). Larger differences were correlated with use of
pecific strategies to reduce the study radiation dose and
ates for Cardiac Studies
Range of Reported Effective
Dose Values (mSv)
Administered
Activity (MBq)
0.05–0.24 N/A
2–16 N/A
12–18 N/A
8–18 N/A
2–4 N/A
7–57 N/A
N/A 1480
N/A 1480
N/A 130
N/A 2960
N/A 740
N/A 185
tomography and prospectively triggered coronary CTA studies published since 2005 only.
l; mSv, millisievert; N/A  not applicable; PA, posteroanterior; and PET, positron emissionstim
tive
mputedith differences in CT equipment (5).
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June 8, 2010:2663–99 Expert Consensus on CT AngiographyIn 2007, the Advanced Cardiovascular Imaging Consor-
ium, a multicenter collaborative quality improvement pro-
ram in Michigan, initiated a prospective best-practices
adiation-dose reduction program at 15 sites (175). Relative
o the control period, the program reduced estimated
edian radiation dose by 53%. Estimated effective dose was
1 mSv in the control period and 10 mSv in the intervention
eriod. The proportion of scans considered of diagnostic
uality was 89% in the control period and 92% in the
ntervention period, indicating no deterioration in image
uality with the radiation-dose reduction protocols.
The risk of developing a malignancy as a stochastic effect
f biologic damage resulting from radiation is extremely
ifficult to ascertain. Several authorities have advocated the
linear no-threshold” hypothesis, which proposes that the
isk of malignancies increases linearly with radiation dose,
ithout a threshold below which radiation cannot cause
alignancies (176). Based on this hypothesis, the age- and
ex-averaged lifetime risk of dying from a malignancy
ttributable to radiation exposure has been estimated to be
pproximately 5 to 7.9 in 100 individuals of the general
opulation per 1 Sv of E (176,177). For a “normal”
opulation, this would translate into an estimated average
ifetime risk of approximately 0.05% to 0.08% of dying from
malignancy resulting from a typical coronary CT angio-
ram with an E of 10 mSv. This risk is superimposed on the
1% intrinsic population-averaged lifetime risk in the
nited States of dying of a malignancy.
In general, radiation exposure and dose are inversely
elated to image noise and, by implication, image quality.
fforts at decreasing radiation exposure and patient dose
hould aim to deliver an image quality that allows confident
mage interpretation. Assuming maintenance of a specific
evel of image noise, radiation dose decreases with:
. Lower tube current (expressed in milliAmpere [mA] or
the product of tube current and exposure time, expressed
in milliAmpere seconds [mAs]).
. Lower tube voltage (peak kiloVolt, kVp).
. Greater slice thickness (mm).
. Higher table advance per gantry rotation expressed as a
fraction of the combined width of all slices acquired
simultaneously (also referred to as “pitch,” which is
dimensionless). A higher value of pitch indicates faster
table advance and, hence, less overlap of irradiation
between successive gantry rotations (178).
. Lower patient body mass (kg).
echnical options for reducing radiation exposure and
atient dose by the practitioner of coronary CTA include:
. Use of the lowest settings of tube current and tube
voltage consistent with diagnostic image quality
(179,180). In the PROTECTION I study, reduced tube
voltage from greater than or equal to 120 to 100 kV was
used in only 5% of subjects but was associated with an (estimated 46% relative reduction in radiation dose and an
improvement in image quality (5).
. Use of ECG-controlled tube current modulation to
reduce tube current during the portions of the cardiac
cycle unlikely to be used for image reconstruction (typ-
ically systole) (180). Increasing the length of time during
the cardiac cycle during which the tube current is
reduced is more feasible in scanners with higher temporal
resolution (181). If during image reconstruction the least
degree of cardiac motion is found during the period of
reduced tube current, the quality of images reconstructed
at that phase of the cardiac cycle may not be optimal due
to low signal-to-noise ratio. In the PROTECTION I
study, ECG-controlled tube current modulation was
used in 73% of patients who had spiral CT data
acquisition and was associated with a 25% relative
reduction in estimated radiation dose in multivariable
analysis but no effect on image quality (5).
. Prospective triggering or “step and shoot” mode with
radiation output only during predetermined portions of
the cardiac cycle (also called sequential scanning) (182).
With the use of prospective triggering, the time point of
optimal image quality with the least degree of cardiac
motion may be missed altogether. In addition, this
method of imaging does not allow for assessment of LV
function since a full 4D dataset is not collected. In the
PROTECTION I study, this method of scanning was
used in only 6% of patients and was associated with a
78% relative reduction in estimated radiation dose rela-
tive to spiral scanning but no effect on image quality (5).
. Heart-rate dependent increase of pitch (181), or elimi-
nating slice overlap altogether (with area detectors or
scanners that can cover the entire length of the heart in
the z-direction with 1 gantry rotation).
1.2. Intravenous Contrast
afe and effective use of contrast media is an important part
f the clinical use of coronary CTA. Aside from allergic
eactions, contrast medium-induced nephropathy is the
ajor safety issue related to contrast administration.
ontrast-induced nephropathy is a form of acute kidney
njury whose pathogenesis is not well understood and is
ikely multifactorial. Possibilities that have been proposed
nclude a direct toxic effect of contrast agent on the tubular
pithelium, oxidative stress, ischemic injury, and tubular
bstruction. Neurohormonal factors have also been impli-
ated in the pathogenesis of contrast-induced nephropathy.
Contrast-induced nephropathy is often defined clinically
y an arbitrary change in renal function. The 2 most
ommon definitions are based on either an absolute change
n serum creatinine of greater than 0.5 mg/dL or a greater
han 25% increase in serum creatinine from baseline within
to 3 days following the exposure to the contrast agent
183). The increase in serum creatinine is often associated
ith adverse clinical outcomes including a higher mortality184–187).
i
f
y
i
g
e
p
u
m
n
m
r
n
n
a
t
w
a
c
d
q
o
p
v
i
i
i
c
a
p
p
a
m
s
v
o
r
a
p
c
d
o
h
c
a
t
t
b
p
m
b
e
t
1
N
g
e
p
w
i
o
d
c
w
t
d
s
d
i
t
f
f
i
w
v
o
c
c
f
t
t
e
a
S
c
(
7
w
m
i
S
w
i
f
g
r
t
a
C
o
2690 Mark et al. JACC Vol. 55, No. 23, 2010
Expert Consensus on CT Angiography June 8, 2010:2663–99Risk factors associated with the development of contrast-
nduced nephropathy include: hypotension, congestive heart
ailure, chronic kidney disease, diabetes, age older than 75
ears, anemia, and volume of contrast (188). An increasing
ncidence of contrast-induced nephropathy with estimated
lomerular filtration rates below 60 mL/min/1.73 m2 was
stablished from retrospective analysis of clinical trials of
atients undergoing coronary angiography. Such analysis
nderscores the importance of pre-existing renal impair-
ent as a major risk factor for developing contrast-induced
ephropathy (189).
The older, ionic, high-osmolar contrast agents are the
edia most likely associated with adverse events in both
outine and high-risk patient populations. Among the
ewer low-osmolar or iso-osmolar contrast agents, there is
o clear consensus on which is the better and safer contrast
gent to use either intravenously or intra-arterially. Prospec-
ive randomized controlled trials comparing iso-osmolar
ith low-osmolar contrast agents have been inconclusive,
nd all contrast agents have the potential of causing
ontrast-induced nephropathy (190–195).
Current generation MDCT scanner technology specially
esigned for imaging human coronary arteries usually re-
uires the use of a higher or even the highest concentration
f iodine as well as faster injection rate to get the best
ossible coronary visualization (196,197). In general, intra-
enous administration of iodine-containing contrast media
s associated with significantly lower incidence of contrast-
nduced nephropathy (0% to 21%) compared with the
ntra-arterial approach. The possible explanation for lower
ontrast-induced nephropathy rates with the intravenous
pproach include the use of lower doses of contrast, less sick
atients with fewer chronic comorbidities, and fewer
rocedure-related complications that might precipitate an
cute renal injury, such as dislodgment of atheromatous
aterial be an intra-aortic catheter or significant hypoten-
ion (198–202).
The writing committee acknowledges the current contro-
ersies in this area, yet feels some measures to minimize the
ccurrence of contrast-induced nephropathy in patients
eferred for coronary CTA seem reasonable to apply across
ll protocols and patients. These should include screening
atients by noting baseline serum creatinine levels and
alculating glomerular filtration rates, noting any history of
iabetes mellitus, CAD, peripheral vascular disease, and
ther underlying conditions that would make the patient
igh risk, avoiding preprocedural dehydration, limiting
ontrast agent dose as much as possible, and ensuring
dequate hydration before and after contrast exposure. Since
he physicians performing the coronary CTA are often not
he physicians involved in the routine care of the patients to
e studied, it is critical that both referring and performing
hysicians communicate about the need and plans for
easures to minimize contrast-induced nephropathy. Ifoth parties recognize the need to be vigilant on this score, crrors of omission are less likely to occur than if each assumes
he other is managing the preprocedure preparations.
2. Cost-Effectiveness Considerations
ational expenditures on health care as a percentage of total
ross domestic product continue to rise each year and now
xceed 15% in the United States. One of the key concerns
ayers and policy makers have with any new test is that it
ill increase total medical expenditures, thereby exacerbat-
ng the already intense competition among healthcare and
ther priorities, such as education, transportation, and
efense, for societal resources. Medical economic analyses
an be very useful in helping to define the efficiency with
hich new medical technologies produce improvements in
he public health. Careful economic analysis is required to
efine whether a new testing strategy may actually recoup
ome or all of its direct costs by eliminating the need for
ownstream tests that would otherwise be used. Of course,
t is also possible that a new testing strategy may increase
otal testing costs in the long run by creating the need for
ollow-up tests that would not otherwise have been per-
ormed. In addition, even if the test does not “pay for itself”
n that manner, cost-effectiveness analysis can define
hether its use for defined clinical indications provides good
alue and make it a more attractive societal investment than
ther less efficient means of improving health.
In general, the literature on the economic effects of
oronary CTA to date is very limited, comprising a few
laims data analyses and several model-based analyses. The
ormer are often limited by the inability to account for all
he relevant clinical details that affect both pre- and post-
est care patterns. The latter are often limited by the lack of
mpirical data relevant to the analysis, and by unrealistic
ssumptions about the patterns of care in the “real world.”
The cost consequences of choosing MDCT versus
PECT MPI in patients without known CAD have re-
ently been explored in a large insurance claims database
203). Comparing 1938 subjects who had an MDCT with
752 subjects who had SPECT showed that initial MDCT
as associated with 16% lower follow-up costs (approxi-
ately $450) exclusive of the costs of the test. Subjects who
nitially received an MDCT were more likely to get a
PECT in follow-up, while subjects who initially under-
ent SPECT were more likely to undergo subsequent
nvasive coronary angiography. At 9 months, rates of
ollow-up revascularization did not differ between the 2
roups. In this data sample, the overall 9-month rate of
evascularization was about 2% with a CAD-related hospi-
alization rate of 4%, implying that the study population had
very low prevalence of significant CAD.
To date, several preliminary economic models of coronary
TA strategies have been published. Such efforts are
bviously limited by the lack of empirical outcome data
urrently available and the resulting need to make major
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June 8, 2010:2663–99 Expert Consensus on CT Angiographynverifiable assumptions about outcomes resulting from a
oronary CTA testing strategy relative to other manage-
ent options. One model was created for the United
ingdom National Health Service in 2007 and considers
lternative diagnostic workup strategies for a stable cohort
ith suspected CAD (48). The primary model was a
hort-term cost minimization model based largely on pooled
iagnostic accuracy data for 8 different diagnostic testing
trategies. Costs were assigned using U.K. prices: exercise
CG £66, exercise MPI £293, 64-channel MDCT £206,
nd invasive coronary angiography £320. Because MDCT
ad a better sensitivity and specificity compared with MPI
nd a lower cost, short-term modeling suggested that
DCT-based strategies would be more economically effi-
ient than MPI-based strategies, although differences nar-
owed somewhat in patients with a higher pretest probabil-
ty of disease. The least expensive strategy overall was
xercise ECG followed by MDCT for patients who had a
ositive or indeterminate result. Need for invasive angiog-
aphy in patients with a positive MDCT increased the
esting costs by about 20% at a 10% pretest probability and
y about 60% at a 50% pretest probability. The most
xpensive strategy at all pretest probabilities was exercise
PI as the initial test with invasive coronary angiography
or a positive or indeterminate result. These results suggest
hat the high sensitivity of MDCT would allow MDCT-
ased strategies to provide an efficient (i.e., lower cost)
valuation of low pretest probability patients, since a nega-
ive test would allow invasive angiography to be avoided.
owever, the assumptions of this model need to be empir-
cally validated since “real life” practice often deviates in a
umber of unanticipated ways from the “ideal” represented
n decision models. In addition, U.S. prices would be
xpected to vary from those in the United Kingdom. Finally,
he modeling does not consider the cost of incidental
ndings on MDCT that require additional work-up.
A cost-effectiveness model created by investigators from
arvard compared the costs and health outcomes of a
oronary CTA-based evaluation strategy with a standard
are strategy using biomarkers and stress testing in patients
ith acute chest pain (204). For this application, there are
ome empirical cost data from the Beaumont Hospital
ingle-center randomized trial (72). The Harvard model
onsidered hypothetical cohorts of 55-year-old men and
omen with acute chest pain being evaluated in the emer-
ency department. The overall prevalence of ACS was
ssumed to be 10% with 2% having stable angina and 88%
aving nonanginal chest pain. In the usual care strategy, the
nvestigators randomly allocated patients to 1 of 3 testing
trategies: stress ECG, stress echo, or stress SPECT. The
esults in the usual care arm reflect the blending of equal
mounts of those 3 strategies. In the men, the coronary
TA strategy increased costs per patient by $200 relative to
sual care, while in women, the coronary CTA strategy
aved $380. This model projected that the coronary CTA
trategy would increase life expectancy by 10 days for men Pnd 6 days for women. The incremental cost-effectiveness of
he coronary CTA strategy in men was estimated at $6400
er quality-adjusted life year added, while for women the
oronary CTA strategy was economically dominant (lower
osts, better quality-adjusted survival). In sensitivity analy-
is, when the usual care strategy was changed to all patients
eceiving stress SPECT MPI, the coronary CTA strategy
as found to be economically dominant for both genders.
In a second decision model–based analysis of the use of
oronary CTA in patients presenting to the emergency
epartment with low-risk chest pain, the strategy of MDCT
rom the emergency department had better outcomes and
ower costs than observation unit care plus either stress
CG or stress echo (205).
The Beaumont Hospital randomized trial together with
he 2 model-based analyses suggest that for low-risk acute
hest pain patients (with pain that is clinically felt to be
oncardiac), coronary CTA may provide an efficient evalu-
tion strategy relative to conventional alternatives. Whether
he strategy also modestly improves long-term outcomes, as
he model-based analyses suggest, will require additional
mpirical data to determine. In addition, the extent to
hich these results apply to intermediate-risk acute chest
ain patients is unclear at present.
3. Quality Considerations
he concept of quality in coronary CTA applies to patient
election, technical training, patient preparation, image
cquisition, physician training, interpretation and reporting
f results, and patient safety. The technical performance of
oronary CTA with modern 64-channel machines is rela-
ively uncomplicated and robust. However, the interpreta-
ive aspects of coronary CTA are inherently more challeng-
ng, as has been discussed in other sections of this
ocument. It is important to note that the clinical studies on
he diagnostic accuracy of coronary CTA reviewed earlier in
his document typically followed detailed protocols for
atient preparation and technician training. And while
echnicians from a broad array of backgrounds can be
rained to perform these studies within a few weeks,
cquisition technique does influence image quality and
herefore can influence diagnostic accuracy. Each laboratory
hould have a routine that assures maximal patient safety
nd the best possible image quality. Physician training
eeded to perform and interpret these studies with a high
evel of quality requires the same sort of structured intensive
raining program needed for high-level competence in other
orms of complex cardiovascular imaging. Thus, short stand-
lone courses that attempt to fast track this process, by
hemselves, would be insufficient for this purpose. The 2005
CCF/AHA Clinical Competence Statement on Cardiac
maging With Computed Tomography and Magnetic Res-
nance (206), the 2006 ACR Practice Guideline for the
erformance and Interpretation of Cardiac Computed To-
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Expert Consensus on CT Angiography June 8, 2010:2663–99ography (207), the 2009 SCCT Guidelines for the Inter-
retation and Reporting of Coronary Computed Tomo-
raphic Angiography (208), the 2008 White Paper from the
CR and NASCI on structured reporting of coronary CTA
209), the 2008 ACCF/ACR/AHA/ASE/ASNC/HRS/
ASCI/RSNA/SAIP/SCAI/SCCT/SCMR Health Policy
tatement on Structured Reporting in Cardiovascular Im-
ging (210), and the ACR Clinical Statement on Noninva-
ive Cardiac Imaging (211) currently serve as reference
oints for the performance and interpretation of cardiac CT.
uidance documents such as these will need to be updated
eriodically as the technology of cardiac CT evolves and as
he knowledge base supporting its clinical use matures. The
005 ACCF/AHA Clinical Competence Statement on
ardiac Imaging With Computed Tomography and Mag-
etic Resonance largely preceded the widespread dissemi-
ation of 64-channel CT machines (206). Although it is
mpossible to know whether most readers today are level 2
r level 3 competent, having this statement as a reference
oint as the technology becomes more widely disseminated
ay assist in improving the overall interpretation quality for
his test in practice. Board certification in cardiovascular CT
y passing a written examination is offered by the Certifi-
ation Board of Cardiovascular Computed Tomography
www.cbcct.org). Future studies are needed to address the
mpact of variability in test performance and interpretation
n the ability of coronary CTA to alter clinical care and
mprove future outcomes. Other important needs include
he development of appropriate quality measures and data
tandards that can allow monitoring of diagnostic perfor-
ance and identify areas for quality improvement. Appro-
riate use criteria needs to be updated as the technology and
upporting evidence base evolve. Finally, close monitoring
f radiation exposure administered to patients is necessary to
eigh the benefits of this noninvasive test and potential
uture unintended consequences and costs.
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